https://trial.medpath.com/news/mirtazapine-shows-promise-for-methamphetamine-use-disorder-in-phase-3-trial 2026-04-02T01:08:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mirtazapine-shows-promise-for-methamphetamine-use-disorder-in-phase-3-trial 2026-04-02T01:08:11+00:00 hourly 0.9 https://trial.medpath.com/news/aav-gene-therapy-pipeline-surpasses-250-candidates-as-fda-approvals-and-late-stage-trials-accelerate-in-2026 2026-04-02T01:08:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aav-gene-therapy-pipeline-surpasses-250-candidates-as-fda-approvals-and-late-stage-trials-accelerate-in-2026 2026-04-02T01:08:07+00:00 hourly 0.9 https://trial.medpath.com/news/fore-biotherapeutics-receives-first-ever-breakthrough-therapy-designation-for-high-grade-glioma-targeted-therapy 2026-04-02T01:06:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fore-biotherapeutics-receives-first-ever-breakthrough-therapy-designation-for-high-grade-glioma-targeted-therapy 2026-04-02T01:06:24+00:00 hourly 0.9 https://trial.medpath.com/news/redwood-ai-partners-with-ubc-to-develop-novel-alzheimer-s-therapeutics-targeting-nudt5-protein 2026-04-02T01:04:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/redwood-ai-partners-with-ubc-to-develop-novel-alzheimer-s-therapeutics-targeting-nudt5-protein 2026-04-02T01:04:21+00:00 hourly 0.9 https://trial.medpath.com/news/single-ketamine-infusion-rapidly-reduces-depression-and-suicidal-thoughts-within-hours-major-review-finds 2026-04-02T01:04:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/single-ketamine-infusion-rapidly-reduces-depression-and-suicidal-thoughts-within-hours-major-review-finds 2026-04-02T01:04:04+00:00 hourly 0.9 https://trial.medpath.com/news/uk-universities-develop-revolutionary-stem-cell-therapy-for-hirschsprung-disease 2026-04-01T21:15:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/uk-universities-develop-revolutionary-stem-cell-therapy-for-hirschsprung-disease 2026-04-01T21:15:26+00:00 hourly 0.9 https://trial.medpath.com/news/marksans-pharma-receives-fda-approval-for-generic-benzonatate-capsules-shares-surge-9 2026-04-01T21:10:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/marksans-pharma-receives-fda-approval-for-generic-benzonatate-capsules-shares-surge-9 2026-04-01T21:10:37+00:00 hourly 0.9 https://trial.medpath.com/news/pulmobiomed-receives-ce-mark-for-first-deep-lung-breath-sampling-device-addressing-40-year-clinical-challenge 2026-04-01T21:09:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pulmobiomed-receives-ce-mark-for-first-deep-lung-breath-sampling-device-addressing-40-year-clinical-challenge 2026-04-01T21:09:48+00:00 hourly 0.9 https://trial.medpath.com/news/syneron-bio-secures-150m-series-b-to-advance-macrocyclic-peptide-drug-discovery-platform 2026-04-01T21:09:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/syneron-bio-secures-150m-series-b-to-advance-macrocyclic-peptide-drug-discovery-platform 2026-04-01T21:09:43+00:00 hourly 0.9 https://trial.medpath.com/news/lord-trial-shows-active-surveillance-may-be-safe-alternative-to-surgery-for-low-risk-dcis 2026-04-01T21:09:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lord-trial-shows-active-surveillance-may-be-safe-alternative-to-surgery-for-low-risk-dcis 2026-04-01T21:09:30+00:00 hourly 0.9 https://trial.medpath.com/news/phase-3-c-diff-vaccine-trial-launches-at-university-of-washington-to-protect-high-risk-older-adults 2026-04-01T21:07:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/phase-3-c-diff-vaccine-trial-launches-at-university-of-washington-to-protect-high-risk-older-adults 2026-04-01T21:07:12+00:00 hourly 0.9 https://trial.medpath.com/news/orion-corporation-appoints-berkeley-vincent-as-executive-vice-president-of-innovative-medicines 2026-04-01T17:09:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/orion-corporation-appoints-berkeley-vincent-as-executive-vice-president-of-innovative-medicines 2026-04-01T17:09:01+00:00 hourly 0.9 https://trial.medpath.com/news/geropharm-advances-biosimilar-development-with-phase-i-trials-for-novo-nordisk-s-diabetes-combination-therapy 2026-04-01T17:06:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/geropharm-advances-biosimilar-development-with-phase-i-trials-for-novo-nordisk-s-diabetes-combination-therapy 2026-04-01T17:06:29+00:00 hourly 0.9 https://trial.medpath.com/news/biontech-to-close-singapore-manufacturing-plant-by-february-2027-amid-revenue-decline 2026-04-01T17:05:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biontech-to-close-singapore-manufacturing-plant-by-february-2027-amid-revenue-decline 2026-04-01T17:05:32+00:00 hourly 0.9 https://trial.medpath.com/news/anixa-biosciences-advances-breast-cancer-vaccine-to-phase-2-following-successful-phase-1-trial 2026-04-01T17:04:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/anixa-biosciences-advances-breast-cancer-vaccine-to-phase-2-following-successful-phase-1-trial 2026-04-01T17:04:30+00:00 hourly 0.9 https://trial.medpath.com/news/thermo-fisher-scientific-launches-next-generation-cell-line-development-platform-to-accelerate-biologics-manufacturing 2026-04-01T17:04:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/thermo-fisher-scientific-launches-next-generation-cell-line-development-platform-to-accelerate-biologics-manufacturing 2026-04-01T17:04:29+00:00 hourly 0.9 https://trial.medpath.com/news/vascarta-s-topical-curcumin-gel-vas-101-shows-significant-pain-reduction-in-knee-osteoarthritis-phase-1b-trial 2026-04-01T17:04:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vascarta-s-topical-curcumin-gel-vas-101-shows-significant-pain-reduction-in-knee-osteoarthritis-phase-1b-trial 2026-04-01T17:04:24+00:00 hourly 0.9 https://trial.medpath.com/news/tango-therapeutics-strengthens-leadership-team-with-key-executive-appointments-to-advance-precision-oncology-pipeline 2026-04-01T17:04:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tango-therapeutics-strengthens-leadership-team-with-key-executive-appointments-to-advance-precision-oncology-pipeline 2026-04-01T17:04:23+00:00 hourly 0.9 https://trial.medpath.com/news/who-recommended-antibiotics-effective-in-only-25-of-neonatal-sepsis-cases-in-low-income-countries 2026-04-01T17:03:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/who-recommended-antibiotics-effective-in-only-25-of-neonatal-sepsis-cases-in-low-income-countries 2026-04-01T17:03:50+00:00 hourly 0.9 https://trial.medpath.com/news/fda-delays-nicotine-pouch-approvals-amid-youth-addiction-concerns 2026-04-01T17:03:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-delays-nicotine-pouch-approvals-amid-youth-addiction-concerns 2026-04-01T17:03:48+00:00 hourly 0.9 https://trial.medpath.com/news/nih-researchers-develop-novel-opioid-dfnz-with-potent-pain-relief-and-reduced-addiction-risk 2026-04-01T17:03:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nih-researchers-develop-novel-opioid-dfnz-with-potent-pain-relief-and-reduced-addiction-risk 2026-04-01T17:03:44+00:00 hourly 0.9 https://trial.medpath.com/news/astrazeneca-s-benralizumab-achieves-50-reduction-in-hes-flares-in-phase-3-trial 2026-04-01T17:03:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/astrazeneca-s-benralizumab-achieves-50-reduction-in-hes-flares-in-phase-3-trial 2026-04-01T17:03:42+00:00 hourly 0.9 https://trial.medpath.com/news/scientists-develop-smart-dna-drug-system-that-targets-cancer-cells-with-computer-like-precision 2026-04-01T13:22:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/scientists-develop-smart-dna-drug-system-that-targets-cancer-cells-with-computer-like-precision 2026-04-01T13:22:46+00:00 hourly 0.9 https://trial.medpath.com/news/symeres-and-ambagon-partner-to-develop-molecular-glue-therapeutics-for-colorectal-cancer 2026-04-01T13:22:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/symeres-and-ambagon-partner-to-develop-molecular-glue-therapeutics-for-colorectal-cancer 2026-04-01T13:22:44+00:00 hourly 0.9 https://trial.medpath.com/news/bd-expands-ai-powered-medication-dispensing-system-to-european-market 2026-04-01T13:22:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bd-expands-ai-powered-medication-dispensing-system-to-european-market 2026-04-01T13:22:40+00:00 hourly 0.9 https://trial.medpath.com/news/fosun-pharma-receives-nmpa-approval-for-phase-1-trial-of-hlx319-biosimilar-for-breast-cancer-treatment 2026-04-01T13:22:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fosun-pharma-receives-nmpa-approval-for-phase-1-trial-of-hlx319-biosimilar-for-breast-cancer-treatment 2026-04-01T13:22:33+00:00 hourly 0.9 https://trial.medpath.com/news/flagship-pioneering-partners-with-aws-to-accelerate-ai-driven-drug-discovery-across-portfolio-companies 2026-04-01T13:21:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/flagship-pioneering-partners-with-aws-to-accelerate-ai-driven-drug-discovery-across-portfolio-companies 2026-04-01T13:21:40+00:00 hourly 0.9 https://trial.medpath.com/news/prism-als-initiative-launches-to-address-critical-gap-in-als-drug-discovery-through-patient-derived-stem-cell-models 2026-04-01T09:05:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/prism-als-initiative-launches-to-address-critical-gap-in-als-drug-discovery-through-patient-derived-stem-cell-models 2026-04-01T09:05:33+00:00 hourly 0.9 https://trial.medpath.com/news/askbio-completes-enrollment-in-phase-2-gene-therapy-trial-for-heart-failure 2026-04-01T09:04:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/askbio-completes-enrollment-in-phase-2-gene-therapy-trial-for-heart-failure 2026-04-01T09:04:57+00:00 hourly 0.9 https://trial.medpath.com/news/nj-bio-and-ajinomoto-bio-pharma-services-partner-to-advance-antibody-drug-conjugate-development-through-ajicaptm-platform-integration 2026-04-01T01:08:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nj-bio-and-ajinomoto-bio-pharma-services-partner-to-advance-antibody-drug-conjugate-development-through-ajicaptm-platform-integration 2026-04-01T01:08:41+00:00 hourly 0.9 https://trial.medpath.com/news/inhibitor-therapeutics-advances-itraconazole-program-for-gorlin-syndrome-with-novel-amorphous-formulation 2026-04-01T01:06:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/inhibitor-therapeutics-advances-itraconazole-program-for-gorlin-syndrome-with-novel-amorphous-formulation 2026-04-01T01:06:55+00:00 hourly 0.9 https://trial.medpath.com/news/india-s-section-3-d-and-compulsory-licensing-how-indian-patent-law-balances-innovation-and-affordable-access-to-life-saving-medicines 2026-04-01T01:06:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/india-s-section-3-d-and-compulsory-licensing-how-indian-patent-law-balances-innovation-and-affordable-access-to-life-saving-medicines 2026-04-01T01:06:48+00:00 hourly 0.9 https://trial.medpath.com/news/high-dose-niacin-shows-promise-in-glioblastoma-early-trial-reports-28-improvement-in-disease-progression 2026-04-01T01:06:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/high-dose-niacin-shows-promise-in-glioblastoma-early-trial-reports-28-improvement-in-disease-progression 2026-04-01T01:06:42+00:00 hourly 0.9 https://trial.medpath.com/news/iontronic-click-to-release-electrically-controlled-drug-delivery-enters-a-new-era 2026-04-01T01:06:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/iontronic-click-to-release-electrically-controlled-drug-delivery-enters-a-new-era 2026-04-01T01:06:24+00:00 hourly 0.9 https://trial.medpath.com/news/kenya-launches-lenacapavir-hiv-prevention-program-but-access-barriers-persist-in-high-risk-communities 2026-04-01T01:05:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kenya-launches-lenacapavir-hiv-prevention-program-but-access-barriers-persist-in-high-risk-communities 2026-04-01T01:05:26+00:00 hourly 0.9 https://trial.medpath.com/news/xbrane-resubmits-ranibizumab-biosimilar-application-to-fda-following-manufacturing-site-corrections 2026-04-01T01:05:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/xbrane-resubmits-ranibizumab-biosimilar-application-to-fda-following-manufacturing-site-corrections 2026-04-01T01:05:26+00:00 hourly 0.9 https://trial.medpath.com/news/lg-chem-acquires-worldwide-rights-to-first-in-class-p53-y220c-cancer-drug-fmc-220 2026-04-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lg-chem-acquires-worldwide-rights-to-first-in-class-p53-y220c-cancer-drug-fmc-220 2026-04-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/pelthos-therapeutics-initiates-phase-1b-2a-trial-of-ct2000-eye-drops-for-chronic-ocular-pain-in-dry-eye-disease 2026-03-31T21:16:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pelthos-therapeutics-initiates-phase-1b-2a-trial-of-ct2000-eye-drops-for-chronic-ocular-pain-in-dry-eye-disease 2026-03-31T21:16:21+00:00 hourly 0.9 https://trial.medpath.com/news/cancervax-achieves-breakthrough-in-targeted-lipid-nanoparticle-delivery-avoiding-liver-toxicity-in-mouse-studies 2026-03-31T21:16:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cancervax-achieves-breakthrough-in-targeted-lipid-nanoparticle-delivery-avoiding-liver-toxicity-in-mouse-studies 2026-03-31T21:16:16+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-first-ever-approval-for-cerebral-venous-stent-to-treat-severe-idiopathic-intracranial-hypertension 2026-03-31T21:15:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-first-ever-approval-for-cerebral-venous-stent-to-treat-severe-idiopathic-intracranial-hypertension 2026-03-31T21:15:36+00:00 hourly 0.9 https://trial.medpath.com/news/affinity-purification-combined-with-vazyme-elisa-sets-new-benchmark-for-dsrna-control-in-mrna-manufacturing 2026-03-31T21:12:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/affinity-purification-combined-with-vazyme-elisa-sets-new-benchmark-for-dsrna-control-in-mrna-manufacturing 2026-03-31T21:12:52+00:00 hourly 0.9 https://trial.medpath.com/news/amylin-drug-development-surges-with-19-billion-investment-as-nearly-40-programs-target-obesity-treatment 2026-03-31T21:09:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/amylin-drug-development-surges-with-19-billion-investment-as-nearly-40-programs-target-obesity-treatment 2026-03-31T21:09:09+00:00 hourly 0.9 https://trial.medpath.com/news/adcytherix-doses-first-patient-in-phase-1-trial-of-adcx-020-marking-transition-to-clinical-stage-company 2026-03-31T17:11:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/adcytherix-doses-first-patient-in-phase-1-trial-of-adcx-020-marking-transition-to-clinical-stage-company 2026-03-31T17:11:35+00:00 hourly 0.9 https://trial.medpath.com/news/tippingpoint-biosciences-secures-4-5m-to-target-undruggable-epigenetic-interfaces-in-pediatric-brain-cancer 2026-03-31T17:08:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tippingpoint-biosciences-secures-4-5m-to-target-undruggable-epigenetic-interfaces-in-pediatric-brain-cancer 2026-03-31T17:08:02+00:00 hourly 0.9 https://trial.medpath.com/news/pheast-therapeutics-advances-phst001-anti-cd24-antibody-into-phase-1b-combination-trials 2026-03-31T17:07:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pheast-therapeutics-advances-phst001-anti-cd24-antibody-into-phase-1b-combination-trials 2026-03-31T17:07:34+00:00 hourly 0.9 https://trial.medpath.com/news/hemogenyx-pharmaceuticals-completes-manufacturing-tech-transfer-for-hg-ct-1-car-t-therapy-expands-clinical-trial-to-pediatric-aml-patients 2026-03-31T17:07:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hemogenyx-pharmaceuticals-completes-manufacturing-tech-transfer-for-hg-ct-1-car-t-therapy-expands-clinical-trial-to-pediatric-aml-patients 2026-03-31T17:07:08+00:00 hourly 0.9 https://trial.medpath.com/news/ambros-therapeutics-secures-key-patent-for-precision-medicine-approach-to-treating-complex-regional-pain-syndrome 2026-03-31T17:06:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ambros-therapeutics-secures-key-patent-for-precision-medicine-approach-to-treating-complex-regional-pain-syndrome 2026-03-31T17:06:44+00:00 hourly 0.9 https://trial.medpath.com/news/enveda-s-env-294-shows-85-easi-reduction-in-phase-1b-atopic-dermatitis-trial 2026-03-31T17:06:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/enveda-s-env-294-shows-85-easi-reduction-in-phase-1b-atopic-dermatitis-trial 2026-03-31T17:06:29+00:00 hourly 0.9 https://trial.medpath.com/news/immunitybio-secures-100-million-in-financing-to-support-global-expansion-of-anktiva-immunotherapy 2026-03-31T17:06:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/immunitybio-secures-100-million-in-financing-to-support-global-expansion-of-anktiva-immunotherapy 2026-03-31T17:06:27+00:00 hourly 0.9 https://trial.medpath.com/news/tarsus-pharmaceuticals-initiates-phase-2-trial-for-first-oral-lyme-disease-prevention-therapy 2026-03-31T17:06:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tarsus-pharmaceuticals-initiates-phase-2-trial-for-first-oral-lyme-disease-prevention-therapy 2026-03-31T17:06:26+00:00 hourly 0.9 https://trial.medpath.com/news/fda-expands-marketing-crackdown-to-cancer-biologics-targets-four-major-companies-over-misleading-survival-claims 2026-03-31T17:05:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-expands-marketing-crackdown-to-cancer-biologics-targets-four-major-companies-over-misleading-survival-claims 2026-03-31T17:05:53+00:00 hourly 0.9 https://trial.medpath.com/news/proxygen-appoints-chiara-conti-as-cso-to-accelerate-molecular-glue-platform-into-clinical-development 2026-03-31T17:05:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/proxygen-appoints-chiara-conti-as-cso-to-accelerate-molecular-glue-platform-into-clinical-development 2026-03-31T17:05:49+00:00 hourly 0.9 https://trial.medpath.com/news/infinimmune-partners-with-merck-in-838-million-antibody-discovery-deal 2026-03-31T17:05:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/infinimmune-partners-with-merck-in-838-million-antibody-discovery-deal 2026-03-31T17:05:44+00:00 hourly 0.9 https://trial.medpath.com/news/cellcentric-launches-pivotal-phase-2-trial-of-inobrodib-combination-for-relapsed-multiple-myeloma 2026-03-31T17:05:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cellcentric-launches-pivotal-phase-2-trial-of-inobrodib-combination-for-relapsed-multiple-myeloma 2026-03-31T17:05:10+00:00 hourly 0.9 https://trial.medpath.com/news/final-arrow-study-data-shows-pralsetinib-achieves-70-response-rate-in-ret-nsclc-with-durable-survival-outcomes 2026-03-31T17:04:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/final-arrow-study-data-shows-pralsetinib-achieves-70-response-rate-in-ret-nsclc-with-durable-survival-outcomes 2026-03-31T17:04:28+00:00 hourly 0.9 https://trial.medpath.com/news/restore-robotics-expands-fda-cleared-robotic-instrument-portfolio-with-two-additional-da-vinci-xi-clearances 2026-03-31T17:04:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/restore-robotics-expands-fda-cleared-robotic-instrument-portfolio-with-two-additional-da-vinci-xi-clearances 2026-03-31T17:04:23+00:00 hourly 0.9 https://trial.medpath.com/news/gan-lee-s-once-weekly-insulin-gzr4-demonstrates-superior-efficacy-in-phase-3-trials 2026-03-31T17:04:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gan-lee-s-once-weekly-insulin-gzr4-demonstrates-superior-efficacy-in-phase-3-trials 2026-03-31T17:04:11+00:00 hourly 0.9 https://trial.medpath.com/news/i-lumen-scientific-receives-fda-ide-approval-to-expand-bioelectric-stimulation-trial-for-dry-amd-to-u-s 2026-03-31T17:04:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/i-lumen-scientific-receives-fda-ide-approval-to-expand-bioelectric-stimulation-trial-for-dry-amd-to-u-s 2026-03-31T17:04:10+00:00 hourly 0.9 https://trial.medpath.com/news/hong-kong-launches-primary-evaluation-system-for-independent-drug-approval 2026-03-31T17:04:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hong-kong-launches-primary-evaluation-system-for-independent-drug-approval 2026-03-31T17:04:03+00:00 hourly 0.9 https://trial.medpath.com/news/altamira-therapeutics-expands-nucleic-acid-delivery-platform-with-dna-technology-and-advances-spin-off-plans 2026-03-31T14:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/altamira-therapeutics-expands-nucleic-acid-delivery-platform-with-dna-technology-and-advances-spin-off-plans 2026-03-31T14:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/eli-lilly-acquires-centessa-pharmaceuticals-for-up-to-7-8-billion-to-expand-sleep-disorder-portfolio 2026-03-31T13:09:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eli-lilly-acquires-centessa-pharmaceuticals-for-up-to-7-8-billion-to-expand-sleep-disorder-portfolio 2026-03-31T13:09:30+00:00 hourly 0.9 https://trial.medpath.com/news/semarion-secures-3-8m-to-scale-cell-based-drug-discovery-platform 2026-03-31T13:08:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/semarion-secures-3-8m-to-scale-cell-based-drug-discovery-platform 2026-03-31T13:08:46+00:00 hourly 0.9 https://trial.medpath.com/news/biogen-acquires-apellis-for-5-6-billion-expanding-immunology-and-rare-disease-portfolio 2026-03-31T13:07:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biogen-acquires-apellis-for-5-6-billion-expanding-immunology-and-rare-disease-portfolio 2026-03-31T13:07:56+00:00 hourly 0.9 https://trial.medpath.com/news/astrazeneca-s-efzimfotase-alfa-shows-promise-in-phase-iii-hypophosphatasia-trials-with-mixed-results 2026-03-31T13:04:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/astrazeneca-s-efzimfotase-alfa-shows-promise-in-phase-iii-hypophosphatasia-trials-with-mixed-results 2026-03-31T13:04:46+00:00 hourly 0.9 https://trial.medpath.com/news/sirpad-trial-demonstrates-superior-efficacy-of-sirolimus-coated-balloons-in-peripheral-artery-disease-treatment 2026-03-31T13:04:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sirpad-trial-demonstrates-superior-efficacy-of-sirolimus-coated-balloons-in-peripheral-artery-disease-treatment 2026-03-31T13:04:45+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-orphan-drug-designation-to-signablok-s-trem-1-inhibitor-for-retinopathy-of-prematurity 2026-03-31T13:04:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-orphan-drug-designation-to-signablok-s-trem-1-inhibitor-for-retinopathy-of-prematurity 2026-03-31T13:04:38+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-fasenra-for-hypereosinophilic-syndrome-based-on-phase-iii-natron-trial-results 2026-03-31T13:04:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-fasenra-for-hypereosinophilic-syndrome-based-on-phase-iii-natron-trial-results 2026-03-31T13:04:06+00:00 hourly 0.9 https://trial.medpath.com/news/signadori-bio-appoints-dr-selwyn-ho-as-ceo-to-advance-novel-monocyte-immunotherapy-platform 2026-03-31T09:04:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/signadori-bio-appoints-dr-selwyn-ho-as-ceo-to-advance-novel-monocyte-immunotherapy-platform 2026-03-31T09:04:57+00:00 hourly 0.9 https://trial.medpath.com/news/bioversys-partners-with-hackensack-meridian-health-to-advance-novel-ansamycin-antibiotics-for-non-tuberculous-mycobacteria 2026-03-31T09:04:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bioversys-partners-with-hackensack-meridian-health-to-advance-novel-ansamycin-antibiotics-for-non-tuberculous-mycobacteria 2026-03-31T09:04:15+00:00 hourly 0.9 https://trial.medpath.com/news/4basebio-expands-manufacturing-capacity-with-new-26500-square-foot-cambridge-facility-to-meet-growing-synthetic-dna-demand 2026-03-31T09:04:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/4basebio-expands-manufacturing-capacity-with-new-26500-square-foot-cambridge-facility-to-meet-growing-synthetic-dna-demand 2026-03-31T09:04:10+00:00 hourly 0.9 https://trial.medpath.com/news/poolbeg-pharma-advances-polb-001-cancer-therapy-with-fda-approval-and-canadian-patent 2026-03-31T09:04:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/poolbeg-pharma-advances-polb-001-cancer-therapy-with-fda-approval-and-canadian-patent 2026-03-31T09:04:08+00:00 hourly 0.9 https://trial.medpath.com/news/toppan-holdings-launches-us-subsidiary-to-advance-personalized-cancer-medicine-using-3d-cell-culture-technology 2026-03-31T09:03:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/toppan-holdings-launches-us-subsidiary-to-advance-personalized-cancer-medicine-using-3d-cell-culture-technology 2026-03-31T09:03:58+00:00 hourly 0.9 https://trial.medpath.com/news/crown-reserve-acquisition-corp-i-and-carvix-announce-1-0-billion-business-combination-agreement 2026-03-31T08:05:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/crown-reserve-acquisition-corp-i-and-carvix-announce-1-0-billion-business-combination-agreement 2026-03-31T08:05:00+00:00 hourly 0.9 https://trial.medpath.com/news/everest-medicines-reports-promising-first-in-human-data-for-personalized-mrna-cancer-vaccine-evm16 2026-03-31T05:04:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/everest-medicines-reports-promising-first-in-human-data-for-personalized-mrna-cancer-vaccine-evm16 2026-03-31T05:04:29+00:00 hourly 0.9 https://trial.medpath.com/news/fluvoxamine-shows-promise-for-long-covid-fatigue-in-international-clinical-trial 2026-03-31T01:05:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fluvoxamine-shows-promise-for-long-covid-fatigue-in-international-clinical-trial 2026-03-31T01:05:59+00:00 hourly 0.9 https://trial.medpath.com/news/fda-clears-ind-for-gene-therapy-candidate-mma-101-to-treat-rare-metabolic-disorder-methylmalonic-acidemia 2026-03-31T01:05:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-clears-ind-for-gene-therapy-candidate-mma-101-to-treat-rare-metabolic-disorder-methylmalonic-acidemia 2026-03-31T01:05:43+00:00 hourly 0.9 https://trial.medpath.com/news/neurocrine-biosciences-acquires-soleno-therapeutics-for-2-9-billion-in-rare-disease-expansion 2026-03-31T01:04:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/neurocrine-biosciences-acquires-soleno-therapeutics-for-2-9-billion-in-rare-disease-expansion 2026-03-31T01:04:32+00:00 hourly 0.9 https://trial.medpath.com/news/haemonetics-receives-fda-approval-for-expanded-vascade-mvp-xl-labeling-to-support-advanced-atrial-fibrillation-procedures 2026-03-31T01:04:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/haemonetics-receives-fda-approval-for-expanded-vascade-mvp-xl-labeling-to-support-advanced-atrial-fibrillation-procedures 2026-03-31T01:04:28+00:00 hourly 0.9 https://trial.medpath.com/news/4dmedical-secures-ce-mark-for-revolutionary-ct-vqtm-lung-imaging-technology-opens-european-market 2026-03-31T01:04:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/4dmedical-secures-ce-mark-for-revolutionary-ct-vqtm-lung-imaging-technology-opens-european-market 2026-03-31T01:04:13+00:00 hourly 0.9 https://trial.medpath.com/news/sharp-quality-leader-advocates-for-supply-chain-wide-quality-culture-beyond-compliance 2026-03-31T00:46:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sharp-quality-leader-advocates-for-supply-chain-wide-quality-culture-beyond-compliance 2026-03-31T00:46:03+00:00 hourly 0.9 https://trial.medpath.com/news/neural-progenitor-cell-transplants-show-promise-for-spinal-cord-repair-through-motor-circuit-reconnection 2026-03-30T21:18:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/neural-progenitor-cell-transplants-show-promise-for-spinal-cord-repair-through-motor-circuit-reconnection 2026-03-30T21:18:26+00:00 hourly 0.9 https://trial.medpath.com/news/butterfly-network-receives-first-fda-clearance-for-ai-powered-gestational-age-ultrasound-tool 2026-03-30T21:17:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/butterfly-network-receives-first-fda-clearance-for-ai-powered-gestational-age-ultrasound-tool 2026-03-30T21:17:08+00:00 hourly 0.9 https://trial.medpath.com/news/triglyceride-lowering-drug-olezarsen-fails-to-reduce-arterial-plaque-despite-60-triglyceride-reduction 2026-03-30T21:16:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/triglyceride-lowering-drug-olezarsen-fails-to-reduce-arterial-plaque-despite-60-triglyceride-reduction 2026-03-30T21:16:31+00:00 hourly 0.9 https://trial.medpath.com/news/merck-s-oral-cholesterol-drug-enlicitide-shows-64-6-ldl-reduction-in-late-stage-trial 2026-03-30T21:15:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/merck-s-oral-cholesterol-drug-enlicitide-shows-64-6-ldl-reduction-in-late-stage-trial 2026-03-30T21:15:56+00:00 hourly 0.9 https://trial.medpath.com/news/smart-decision-trial-shows-beta-blocker-discontinuation-safe-for-low-risk-post-mi-patients 2026-03-30T21:15:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/smart-decision-trial-shows-beta-blocker-discontinuation-safe-for-low-risk-post-mi-patients 2026-03-30T21:15:08+00:00 hourly 0.9 https://trial.medpath.com/news/ap-biosciences-and-tasly-amend-collaboration-to-accelerate-global-development-of-dual-target-cancer-therapy-ap505 2026-03-30T21:14:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ap-biosciences-and-tasly-amend-collaboration-to-accelerate-global-development-of-dual-target-cancer-therapy-ap505 2026-03-30T21:14:32+00:00 hourly 0.9 https://trial.medpath.com/news/cynata-therapeutics-completes-phase-2-trial-evaluation-for-stem-cell-therapy-targeting-acute-graft-versus-host-disease 2026-03-30T21:13:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cynata-therapeutics-completes-phase-2-trial-evaluation-for-stem-cell-therapy-targeting-acute-graft-versus-host-disease 2026-03-30T21:13:51+00:00 hourly 0.9 https://trial.medpath.com/news/blackstone-closes-record-6-3-billion-life-sciences-fund-largest-private-investment-vehicle-in-sector-history 2026-03-30T21:12:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/blackstone-closes-record-6-3-billion-life-sciences-fund-largest-private-investment-vehicle-in-sector-history 2026-03-30T21:12:42+00:00 hourly 0.9 https://trial.medpath.com/news/university-of-arizona-launches-12-million-phase-3-trial-testing-rapamycin-for-healthy-aging 2026-03-30T21:09:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/university-of-arizona-launches-12-million-phase-3-trial-testing-rapamycin-for-healthy-aging 2026-03-30T21:09:40+00:00 hourly 0.9 https://trial.medpath.com/news/bullfrog-ai-secures-major-commercial-agreement-with-top-5-pharma-company-for-ai-driven-depression-drug-discovery 2026-03-30T17:13:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bullfrog-ai-secures-major-commercial-agreement-with-top-5-pharma-company-for-ai-driven-depression-drug-discovery 2026-03-30T17:13:27+00:00 hourly 0.9 https://trial.medpath.com/news/hengrui-pharma-and-braveheart-bio-report-promising-phase-2-results-for-next-generation-cardiac-myosin-inhibitor-in-obstructive-hypertrophic-cardiomyopathy 2026-03-30T17:12:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hengrui-pharma-and-braveheart-bio-report-promising-phase-2-results-for-next-generation-cardiac-myosin-inhibitor-in-obstructive-hypertrophic-cardiomyopathy 2026-03-30T17:12:22+00:00 hourly 0.9 https://trial.medpath.com/news/j-j-s-spravato-shows-sustained-antidepressant-effects-six-months-after-treatment-discontinuation-in-real-world-study 2026-03-30T17:12:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/j-j-s-spravato-shows-sustained-antidepressant-effects-six-months-after-treatment-discontinuation-in-real-world-study 2026-03-30T17:12:13+00:00 hourly 0.9 https://trial.medpath.com/news/tartan-hf-trial-reveals-one-in-four-diabetics-has-undiagnosed-heart-failure 2026-03-30T17:08:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tartan-hf-trial-reveals-one-in-four-diabetics-has-undiagnosed-heart-failure 2026-03-30T17:08:53+00:00 hourly 0.9 https://trial.medpath.com/news/fda-clears-ultragenyx-ind-application-for-ux016-to-treat-rare-gne-myopathy 2026-03-30T17:08:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-clears-ultragenyx-ind-application-for-ux016-to-treat-rare-gne-myopathy 2026-03-30T17:08:24+00:00 hourly 0.9 https://trial.medpath.com/news/calliditas-therapeutics-presents-new-nefigard-trial-data-supporting-nefecon-s-gut-targeted-mechanism-in-iga-nephropathy 2026-03-30T17:08:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/calliditas-therapeutics-presents-new-nefigard-trial-data-supporting-nefecon-s-gut-targeted-mechanism-in-iga-nephropathy 2026-03-30T17:08:12+00:00 hourly 0.9 https://trial.medpath.com/news/emboline-s-emboliner-system-achieves-superior-debris-capture-in-pivotal-tavr-protection-trial 2026-03-30T17:05:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/emboline-s-emboliner-system-achieves-superior-debris-capture-in-pivotal-tavr-protection-trial 2026-03-30T17:05:58+00:00 hourly 0.9 https://trial.medpath.com/news/vor-bio-initiates-global-phase-3-trial-of-telitacicept-for-primary-sjogren-s-disease 2026-03-30T13:09:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vor-bio-initiates-global-phase-3-trial-of-telitacicept-for-primary-sjogren-s-disease 2026-03-30T13:09:20+00:00 hourly 0.9 https://trial.medpath.com/news/novartis-and-abbvie-sue-washington-state-over-new-340b-drug-pricing-transparency-law 2026-03-30T13:08:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novartis-and-abbvie-sue-washington-state-over-new-340b-drug-pricing-transparency-law 2026-03-30T13:08:32+00:00 hourly 0.9 https://trial.medpath.com/news/prilenia-and-ferrer-launch-pivotal-phase-3-trial-of-pridopidine-for-rapidly-progressive-als 2026-03-30T13:06:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/prilenia-and-ferrer-launch-pivotal-phase-3-trial-of-pridopidine-for-rapidly-progressive-als 2026-03-30T13:06:47+00:00 hourly 0.9 https://trial.medpath.com/news/dompe-initiates-phase-2-trial-of-intranasal-ngf-for-spastic-cerebral-palsy-in-italy 2026-03-30T13:05:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dompe-initiates-phase-2-trial-of-intranasal-ngf-for-spastic-cerebral-palsy-in-italy 2026-03-30T13:05:13+00:00 hourly 0.9 https://trial.medpath.com/news/boston-scientific-receives-fda-clearance-for-asurys-fluid-management-system-to-address-kidney-stone-treatment-challenges 2026-03-30T13:05:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/boston-scientific-receives-fda-clearance-for-asurys-fluid-management-system-to-address-kidney-stone-treatment-challenges 2026-03-30T13:05:06+00:00 hourly 0.9 https://trial.medpath.com/news/harmonicare-receives-fda-approval-for-fgfr2-3-inhibitor-absk061-clinical-trial-in-pediatric-achondroplasia 2026-03-30T13:04:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/harmonicare-receives-fda-approval-for-fgfr2-3-inhibitor-absk061-clinical-trial-in-pediatric-achondroplasia 2026-03-30T13:04:42+00:00 hourly 0.9 https://trial.medpath.com/news/nanobiotix-reports-promising-early-data-from-phase-2-lung-cancer-trial-of-jnj-1900-radioenhancer 2026-03-30T09:08:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nanobiotix-reports-promising-early-data-from-phase-2-lung-cancer-trial-of-jnj-1900-radioenhancer 2026-03-30T09:08:42+00:00 hourly 0.9 https://trial.medpath.com/news/roche-launches-cobas-mpx-e-assay-revolutionary-4-in-1-blood-screening-test-enhances-global-blood-supply-safety 2026-03-30T09:07:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/roche-launches-cobas-mpx-e-assay-revolutionary-4-in-1-blood-screening-test-enhances-global-blood-supply-safety 2026-03-30T09:07:57+00:00 hourly 0.9 https://trial.medpath.com/news/algorae-pharmaceuticals-advances-ai-driven-drug-discovery-with-second-peter-maccallum-cancer-centre-collaboration 2026-03-30T09:07:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/algorae-pharmaceuticals-advances-ai-driven-drug-discovery-with-second-peter-maccallum-cancer-centre-collaboration 2026-03-30T09:07:27+00:00 hourly 0.9 https://trial.medpath.com/news/noninvasive-lung-impedance-monitoring-cuts-heart-failure-hospitalizations-by-74-in-hfpef-patients 2026-03-30T05:06:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/noninvasive-lung-impedance-monitoring-cuts-heart-failure-hospitalizations-by-74-in-hfpef-patients 2026-03-30T05:06:59+00:00 hourly 0.9 https://trial.medpath.com/news/nih-commits-720k-to-co-fund-phase-ii-mesenchymal-stem-cell-trial-for-moderate-to-severe-lupus 2026-03-30T05:05:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nih-commits-720k-to-co-fund-phase-ii-mesenchymal-stem-cell-trial-for-moderate-to-severe-lupus 2026-03-30T05:05:51+00:00 hourly 0.9 https://trial.medpath.com/news/revolutionary-microneedle-patch-enables-non-invasive-immune-system-monitoring 2026-03-30T01:07:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/revolutionary-microneedle-patch-enables-non-invasive-immune-system-monitoring 2026-03-30T01:07:07+00:00 hourly 0.9 https://trial.medpath.com/news/first-placebo-controlled-trial-shows-angioplasty-significantly-reduces-angina-in-chronic-total-occlusion-patients 2026-03-30T01:07:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/first-placebo-controlled-trial-shows-angioplasty-significantly-reduces-angina-in-chronic-total-occlusion-patients 2026-03-30T01:07:02+00:00 hourly 0.9 https://trial.medpath.com/news/mrna-lnp-therapy-with-mtor-inhibition-reprograms-allergic-responses-in-preclinical-model 2026-03-29T21:06:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mrna-lnp-therapy-with-mtor-inhibition-reprograms-allergic-responses-in-preclinical-model 2026-03-29T21:06:01+00:00 hourly 0.9 https://trial.medpath.com/news/spirit-hf-trial-shows-no-benefit-and-safety-concerns-for-spironolactone-in-heart-failure-with-preserved-ejection-fraction 2026-03-29T21:05:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/spirit-hf-trial-shows-no-benefit-and-safety-concerns-for-spironolactone-in-heart-failure-with-preserved-ejection-fraction 2026-03-29T21:05:47+00:00 hourly 0.9 https://trial.medpath.com/news/real-world-study-confirms-safety-of-biologic-therapies-in-asthma-shows-reduced-pneumonia-risk 2026-03-29T21:05:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/real-world-study-confirms-safety-of-biologic-therapies-in-asthma-shows-reduced-pneumonia-risk 2026-03-29T21:05:33+00:00 hourly 0.9 https://trial.medpath.com/news/bristol-myers-squibb-s-cobenfy-shows-stable-transition-profile-in-phase-4-schizophrenia-trial 2026-03-29T17:07:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bristol-myers-squibb-s-cobenfy-shows-stable-transition-profile-in-phase-4-schizophrenia-trial 2026-03-29T17:07:05+00:00 hourly 0.9 https://trial.medpath.com/news/yingen-bio-s-her2-adc-db-1303-receives-marketing-approval-acceptance-in-china-for-breast-cancer-treatment 2026-03-29T17:06:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/yingen-bio-s-her2-adc-db-1303-receives-marketing-approval-acceptance-in-china-for-breast-cancer-treatment 2026-03-29T17:06:58+00:00 hourly 0.9 https://trial.medpath.com/news/key-phase-3-trials-from-moderna-sarepta-and-krystal-biotech-set-to-drive-2026-biotech-performance 2026-03-29T17:06:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/key-phase-3-trials-from-moderna-sarepta-and-krystal-biotech-set-to-drive-2026-biotech-performance 2026-03-29T17:06:05+00:00 hourly 0.9 https://trial.medpath.com/news/fast-iii-trial-shows-non-invasive-vffr-technology-matches-gold-standard-ffr-for-coronary-revascularization-guidance 2026-03-29T17:04:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fast-iii-trial-shows-non-invasive-vffr-technology-matches-gold-standard-ffr-for-coronary-revascularization-guidance 2026-03-29T17:04:49+00:00 hourly 0.9 https://trial.medpath.com/news/eli-lilly-abandons-pbs-negotiations-for-mounjaro-leaving-450000-australians-without-subsidized-access 2026-03-29T17:04:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eli-lilly-abandons-pbs-negotiations-for-mounjaro-leaving-450000-australians-without-subsidized-access 2026-03-29T17:04:44+00:00 hourly 0.9 https://trial.medpath.com/news/grand-pharmaceutical-secures-china-approval-for-eye-treatment-gpn01768-advances-migraine-drug-to-phase-ii 2026-03-29T13:05:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/grand-pharmaceutical-secures-china-approval-for-eye-treatment-gpn01768-advances-migraine-drug-to-phase-ii 2026-03-29T13:05:10+00:00 hourly 0.9 https://trial.medpath.com/news/remegen-secures-nmpa-approval-for-phase-i-iia-trial-of-bispecific-adc-rc288-in-solid-tumors 2026-03-29T05:04:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/remegen-secures-nmpa-approval-for-phase-i-iia-trial-of-bispecific-adc-rc288-in-solid-tumors 2026-03-29T05:04:41+00:00 hourly 0.9 https://trial.medpath.com/news/tonlamarsen-shows-promise-in-resistant-hypertension-despite-mixed-phase-2-results 2026-03-29T01:04:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tonlamarsen-shows-promise-in-resistant-hypertension-despite-mixed-phase-2-results 2026-03-29T01:04:48+00:00 hourly 0.9 https://trial.medpath.com/news/repatha-reduces-first-major-cardiovascular-events-by-31-in-high-risk-patients-without-significant-atherosclerosis 2026-03-29T01:04:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/repatha-reduces-first-major-cardiovascular-events-by-31-in-high-risk-patients-without-significant-atherosclerosis 2026-03-29T01:04:44+00:00 hourly 0.9 https://trial.medpath.com/news/tens-therapy-shows-sustained-pain-relief-for-fibromyalgia-patients-in-large-real-world-trial 2026-03-28T21:10:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tens-therapy-shows-sustained-pain-relief-for-fibromyalgia-patients-in-large-real-world-trial 2026-03-28T21:10:40+00:00 hourly 0.9 https://trial.medpath.com/news/anumana-receives-fda-clearance-for-first-ecg-ai-algorithm-to-detect-early-pulmonary-hypertension 2026-03-28T21:10:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/anumana-receives-fda-clearance-for-first-ecg-ai-algorithm-to-detect-early-pulmonary-hypertension 2026-03-28T21:10:39+00:00 hourly 0.9 https://trial.medpath.com/news/incyte-s-povorcitinib-shows-71-response-rate-in-late-stage-hidradenitis-suppurativa-trials 2026-03-28T21:08:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/incyte-s-povorcitinib-shows-71-response-rate-in-late-stage-hidradenitis-suppurativa-trials 2026-03-28T21:08:33+00:00 hourly 0.9 https://trial.medpath.com/news/boston-scientific-s-ekos-system-shows-superior-outcomes-in-pulmonary-embolism-treatment 2026-03-28T21:07:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/boston-scientific-s-ekos-system-shows-superior-outcomes-in-pulmonary-embolism-treatment 2026-03-28T21:07:22+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-bayer-s-lynkuet-as-first-nonhormonal-menopause-treatment-for-hot-flashes 2026-03-28T21:07:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-bayer-s-lynkuet-as-first-nonhormonal-menopause-treatment-for-hot-flashes 2026-03-28T21:07:15+00:00 hourly 0.9 https://trial.medpath.com/news/impella-cp-heart-pump-fails-to-reduce-infarct-size-in-major-stemi-trial 2026-03-28T17:08:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/impella-cp-heart-pump-fails-to-reduce-infarct-size-in-major-stemi-trial 2026-03-28T17:08:58+00:00 hourly 0.9 https://trial.medpath.com/news/champion-af-trial-shows-watchman-flx-device-non-inferior-to-blood-thinners-for-stroke-prevention-in-atrial-fibrillation 2026-03-28T17:06:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/champion-af-trial-shows-watchman-flx-device-non-inferior-to-blood-thinners-for-stroke-prevention-in-atrial-fibrillation 2026-03-28T17:06:52+00:00 hourly 0.9 https://trial.medpath.com/news/iterum-therapeutics-seeks-court-led-dissolution-following-failed-fundraising-and-orlynvah-sales-struggles 2026-03-28T13:05:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/iterum-therapeutics-seeks-court-led-dissolution-following-failed-fundraising-and-orlynvah-sales-struggles 2026-03-28T13:05:00+00:00 hourly 0.9 https://trial.medpath.com/news/portable-tacs-shows-promise-for-treatment-resistant-depression-in-multicenter-randomized-trial 2026-03-28T10:41:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/portable-tacs-shows-promise-for-treatment-resistant-depression-in-multicenter-randomized-trial 2026-03-28T10:41:24+00:00 hourly 0.9 https://trial.medpath.com/news/university-of-manchester-receives-ps1-million-to-develop-snail-inspired-soft-robots-for-bowel-cancer-drug-delivery 2026-03-28T05:05:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/university-of-manchester-receives-ps1-million-to-develop-snail-inspired-soft-robots-for-bowel-cancer-drug-delivery 2026-03-28T05:05:55+00:00 hourly 0.9 https://trial.medpath.com/news/biocon-appoints-shreehas-tambe-as-ceo-following-major-organizational-restructuring 2026-03-28T05:04:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biocon-appoints-shreehas-tambe-as-ceo-following-major-organizational-restructuring 2026-03-28T05:04:41+00:00 hourly 0.9 https://trial.medpath.com/news/bamf-health-advances-theranostic-treatment-for-colorectal-cancer-in-west-michigan-clinical-trials 2026-03-28T01:06:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bamf-health-advances-theranostic-treatment-for-colorectal-cancer-in-west-michigan-clinical-trials 2026-03-28T01:06:54+00:00 hourly 0.9 https://trial.medpath.com/news/pig-semen-derived-eye-drops-show-promise-for-retinoblastoma-treatment-in-preclinical-studies 2026-03-28T01:05:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pig-semen-derived-eye-drops-show-promise-for-retinoblastoma-treatment-in-preclinical-studies 2026-03-28T01:05:57+00:00 hourly 0.9 https://trial.medpath.com/news/sun-pharma-s-fibromun-and-nidlegy-face-mixed-clinical-trial-results-in-cancer-studies 2026-03-28T01:05:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sun-pharma-s-fibromun-and-nidlegy-face-mixed-clinical-trial-results-in-cancer-studies 2026-03-28T01:05:38+00:00 hourly 0.9 https://trial.medpath.com/news/researchers-develop-wireless-implantable-device-to-solve-oxygen-challenge-in-cell-based-drug-delivery 2026-03-28T01:04:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/researchers-develop-wireless-implantable-device-to-solve-oxygen-challenge-in-cell-based-drug-delivery 2026-03-28T01:04:54+00:00 hourly 0.9 https://trial.medpath.com/news/low-dose-ct-screening-reduces-lung-cancer-mortality-by-55-in-non-risk-based-population 2026-03-27T21:06:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/low-dose-ct-screening-reduces-lung-cancer-mortality-by-55-in-non-risk-based-population 2026-03-27T21:06:23+00:00 hourly 0.9 https://trial.medpath.com/news/ysios-capital-launches-eur100m-inceptionbio-fund-to-catalyze-spanish-biotech-spinouts 2026-03-27T21:05:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ysios-capital-launches-eur100m-inceptionbio-fund-to-catalyze-spanish-biotech-spinouts 2026-03-27T21:05:28+00:00 hourly 0.9 https://trial.medpath.com/news/nkarta-secures-fda-approval-for-outpatient-car-nk-cell-therapy-administration-in-autoimmune-disease-trials 2026-03-27T17:12:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nkarta-secures-fda-approval-for-outpatient-car-nk-cell-therapy-administration-in-autoimmune-disease-trials 2026-03-27T17:12:17+00:00 hourly 0.9 https://trial.medpath.com/news/fda-clears-phase-1-pediatric-cns-cancer-trial-for-star-001-combination-therapy 2026-03-27T17:11:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-clears-phase-1-pediatric-cns-cancer-trial-for-star-001-combination-therapy 2026-03-27T17:11:22+00:00 hourly 0.9 https://trial.medpath.com/news/northwestern-team-develops-implantable-living-pharmacy-device-that-produces-multiple-drugs-simultaneously 2026-03-27T17:09:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/northwestern-team-develops-implantable-living-pharmacy-device-that-produces-multiple-drugs-simultaneously 2026-03-27T17:09:01+00:00 hourly 0.9 https://trial.medpath.com/news/ema-recommends-approval-of-amgen-s-tarlatamab-for-relapsed-small-cell-lung-cancer 2026-03-27T17:07:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ema-recommends-approval-of-amgen-s-tarlatamab-for-relapsed-small-cell-lung-cancer 2026-03-27T17:07:56+00:00 hourly 0.9 https://trial.medpath.com/news/otsuka-acquires-transcend-therapeutics-for-1-2-billion-to-advance-ptsd-treatment-with-breakthrough-therapy-tsnd-201 2026-03-27T17:06:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/otsuka-acquires-transcend-therapeutics-for-1-2-billion-to-advance-ptsd-treatment-with-breakthrough-therapy-tsnd-201 2026-03-27T17:06:20+00:00 hourly 0.9 https://trial.medpath.com/news/arletta-pharma-s-lybridotm-shows-statistically-significant-improvement-in-female-sexual-dysfunction-phase-ii-trial 2026-03-27T17:06:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/arletta-pharma-s-lybridotm-shows-statistically-significant-improvement-in-female-sexual-dysfunction-phase-ii-trial 2026-03-27T17:06:19+00:00 hourly 0.9 https://trial.medpath.com/news/prf-technologies-advances-ocuring-k-intraocular-ring-for-cataract-surgery-through-phase-i-safety-studies 2026-03-27T13:07:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/prf-technologies-advances-ocuring-k-intraocular-ring-for-cataract-surgery-through-phase-i-safety-studies 2026-03-27T13:07:00+00:00 hourly 0.9 https://trial.medpath.com/news/novartis-acquires-excellergy-for-up-to-2-billion-to-strengthen-immunology-portfolio 2026-03-27T13:05:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novartis-acquires-excellergy-for-up-to-2-billion-to-strengthen-immunology-portfolio 2026-03-27T13:05:47+00:00 hourly 0.9 https://trial.medpath.com/news/astrazeneca-s-tozorakimab-achieves-primary-endpoints-in-phase-iii-copd-trials-demonstrating-significant-reduction-in-exacerbations 2026-03-27T13:05:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/astrazeneca-s-tozorakimab-achieves-primary-endpoints-in-phase-iii-copd-trials-demonstrating-significant-reduction-in-exacerbations 2026-03-27T13:05:07+00:00 hourly 0.9 https://trial.medpath.com/news/lifecore-biomedical-secures-two-new-cdmo-agreements-including-fourth-commercial-site-transfer-in-five-months 2026-03-27T09:06:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lifecore-biomedical-secures-two-new-cdmo-agreements-including-fourth-commercial-site-transfer-in-five-months 2026-03-27T09:06:10+00:00 hourly 0.9 https://trial.medpath.com/news/espresso-trial-challenges-more-therapy-earlier-paradigm-in-stroke-rehabilitation 2026-03-27T09:05:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/espresso-trial-challenges-more-therapy-earlier-paradigm-in-stroke-rehabilitation 2026-03-27T09:05:40+00:00 hourly 0.9 https://trial.medpath.com/news/intelligent-bio-solutions-secures-eighth-european-patent-for-advanced-fingerprint-drug-testing-technology 2026-03-27T05:06:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/intelligent-bio-solutions-secures-eighth-european-patent-for-advanced-fingerprint-drug-testing-technology 2026-03-27T05:06:12+00:00 hourly 0.9 https://trial.medpath.com/news/pinnacle-medicines-raises-89-million-series-b-to-advance-oral-peptide-therapeutics-into-clinical-trials 2026-03-27T05:05:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pinnacle-medicines-raises-89-million-series-b-to-advance-oral-peptide-therapeutics-into-clinical-trials 2026-03-27T05:05:32+00:00 hourly 0.9 https://trial.medpath.com/news/lunai-bioworks-acquires-blood-brain-barrier-delivery-platform-in-20m-deal-to-advance-alzheimer-s-therapeutics 2026-03-27T01:08:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lunai-bioworks-acquires-blood-brain-barrier-delivery-platform-in-20m-deal-to-advance-alzheimer-s-therapeutics 2026-03-27T01:08:19+00:00 hourly 0.9 https://trial.medpath.com/news/allogene-therapeutics-reports-promising-data-for-off-the-shelf-car-t-therapy-in-b-cell-lymphoma 2026-03-27T01:07:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/allogene-therapeutics-reports-promising-data-for-off-the-shelf-car-t-therapy-in-b-cell-lymphoma 2026-03-27T01:07:34+00:00 hourly 0.9 https://trial.medpath.com/news/vivani-medical-advances-npm-139-semaglutide-implant-toward-phase-1-trial-following-successful-preclinical-data 2026-03-27T01:06:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vivani-medical-advances-npm-139-semaglutide-implant-toward-phase-1-trial-following-successful-preclinical-data 2026-03-27T01:06:36+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-novo-nordisk-s-awiqli-first-once-weekly-basal-insulin-for-type-2-diabetes 2026-03-27T01:06:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-novo-nordisk-s-awiqli-first-once-weekly-basal-insulin-for-type-2-diabetes 2026-03-27T01:06:34+00:00 hourly 0.9 https://trial.medpath.com/news/metformin-s-anti-diabetic-effects-linked-to-brain-mechanism-involving-rap1-protein 2026-03-27T01:06:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/metformin-s-anti-diabetic-effects-linked-to-brain-mechanism-involving-rap1-protein 2026-03-27T01:06:33+00:00 hourly 0.9 https://trial.medpath.com/news/rubedo-life-sciences-reports-positive-phase-1-results-for-first-in-class-gpx4-modulator-rls-1496-in-dermatological-conditions 2026-03-27T01:06:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rubedo-life-sciences-reports-positive-phase-1-results-for-first-in-class-gpx4-modulator-rls-1496-in-dermatological-conditions 2026-03-27T01:06:26+00:00 hourly 0.9 https://trial.medpath.com/news/humacyte-appoints-rick-mcelheny-as-senior-vp-of-business-development-to-accelerate-bioengineered-tissue-partnerships 2026-03-26T21:07:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/humacyte-appoints-rick-mcelheny-as-senior-vp-of-business-development-to-accelerate-bioengineered-tissue-partnerships 2026-03-26T21:07:25+00:00 hourly 0.9 https://trial.medpath.com/news/low-dose-cd7-car-t-cell-therapy-shows-93-5-response-rate-in-relapsed-t-cell-lymphomas 2026-03-26T21:07:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/low-dose-cd7-car-t-cell-therapy-shows-93-5-response-rate-in-relapsed-t-cell-lymphomas 2026-03-26T21:07:03+00:00 hourly 0.9 https://trial.medpath.com/news/herbalife-acquires-personalized-supplement-startup-bioniq-for-up-to-150m-to-scale-data-driven-nutrition 2026-03-26T21:06:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/herbalife-acquires-personalized-supplement-startup-bioniq-for-up-to-150m-to-scale-data-driven-nutrition 2026-03-26T21:06:23+00:00 hourly 0.9 https://trial.medpath.com/news/pulmatrix-and-eos-senolytix-announce-19-million-merger-to-advance-anti-aging-mitochondrial-therapies 2026-03-26T21:04:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pulmatrix-and-eos-senolytix-announce-19-million-merger-to-advance-anti-aging-mitochondrial-therapies 2026-03-26T21:04:48+00:00 hourly 0.9 https://trial.medpath.com/news/oig-approves-medicare-cost-sharing-subsidies-for-heart-failure-device-clinical-trial 2026-03-26T17:10:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/oig-approves-medicare-cost-sharing-subsidies-for-heart-failure-device-clinical-trial 2026-03-26T17:10:31+00:00 hourly 0.9 https://trial.medpath.com/news/eurofins-viracor-launches-rapid-car-t-cell-monitoring-assay-for-obe-cel-therapy 2026-03-26T17:09:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eurofins-viracor-launches-rapid-car-t-cell-monitoring-assay-for-obe-cel-therapy 2026-03-26T17:09:31+00:00 hourly 0.9 https://trial.medpath.com/news/quantum-biopharma-appoints-principal-investigator-for-phase-2-multiple-sclerosis-trial-of-lucid-ms 2026-03-26T17:08:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/quantum-biopharma-appoints-principal-investigator-for-phase-2-multiple-sclerosis-trial-of-lucid-ms 2026-03-26T17:08:46+00:00 hourly 0.9 https://trial.medpath.com/news/made-scientific-partners-with-njit-to-launch-graduate-cell-and-gene-therapy-bioprocessing-program 2026-03-26T17:08:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/made-scientific-partners-with-njit-to-launch-graduate-cell-and-gene-therapy-bioprocessing-program 2026-03-26T17:08:43+00:00 hourly 0.9 https://trial.medpath.com/news/kodiak-sciences-zenkuda-achieves-primary-endpoint-in-phase-3-diabetic-retinopathy-trial 2026-03-26T17:07:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kodiak-sciences-zenkuda-achieves-primary-endpoint-in-phase-3-diabetic-retinopathy-trial 2026-03-26T17:07:29+00:00 hourly 0.9 https://trial.medpath.com/news/sino-biopharm-reports-strong-2025-results-with-26-2-growth-in-innovative-drug-sales 2026-03-26T17:06:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sino-biopharm-reports-strong-2025-results-with-26-2-growth-in-innovative-drug-sales 2026-03-26T17:06:55+00:00 hourly 0.9 https://trial.medpath.com/news/kamada-secures-fda-approval-for-san-antonio-plasma-collection-center-expanding-specialty-plasma-production-capacity 2026-03-26T17:06:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kamada-secures-fda-approval-for-san-antonio-plasma-collection-center-expanding-specialty-plasma-production-capacity 2026-03-26T17:06:45+00:00 hourly 0.9 https://trial.medpath.com/news/kodiak-sciences-zenkuda-achieves-62-5-response-rate-in-phase-3-glow2-diabetic-retinopathy-trial 2026-03-26T17:06:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kodiak-sciences-zenkuda-achieves-62-5-response-rate-in-phase-3-glow2-diabetic-retinopathy-trial 2026-03-26T17:06:44+00:00 hourly 0.9 https://trial.medpath.com/news/meiragtx-receives-fda-breakthrough-therapy-designation-for-gene-therapy-treating-radiation-induced-dry-mouth 2026-03-26T17:06:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/meiragtx-receives-fda-breakthrough-therapy-designation-for-gene-therapy-treating-radiation-induced-dry-mouth 2026-03-26T17:06:21+00:00 hourly 0.9 https://trial.medpath.com/news/mytomorrows-partners-with-spanish-academic-hospital-to-deploy-ai-powered-clinical-trial-matching-system 2026-03-26T17:05:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mytomorrows-partners-with-spanish-academic-hospital-to-deploy-ai-powered-clinical-trial-matching-system 2026-03-26T17:05:55+00:00 hourly 0.9 https://trial.medpath.com/news/edesa-biotech-prepares-phase-2-vitiligo-trial-for-mid-2026-launch-following-promising-ards-results 2026-03-26T17:05:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/edesa-biotech-prepares-phase-2-vitiligo-trial-for-mid-2026-launch-following-promising-ards-results 2026-03-26T17:05:43+00:00 hourly 0.9 https://trial.medpath.com/news/neion-bio-secures-23m-series-a-to-scale-egg-based-biologics-manufacturing-platform 2026-03-26T13:33:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/neion-bio-secures-23m-series-a-to-scale-egg-based-biologics-manufacturing-platform 2026-03-26T13:33:00+00:00 hourly 0.9 https://trial.medpath.com/news/bioptimus-launches-stela-world-s-largest-spatial-biology-atlas-to-power-ai-driven-precision-medicine 2026-03-26T13:08:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bioptimus-launches-stela-world-s-largest-spatial-biology-atlas-to-power-ai-driven-precision-medicine 2026-03-26T13:08:15+00:00 hourly 0.9 https://trial.medpath.com/news/invivoscribe-achieves-ivdr-class-c-certification-for-b-cell-lymphoma-diagnostic-assay-in-europe 2026-03-26T13:08:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/invivoscribe-achieves-ivdr-class-c-certification-for-b-cell-lymphoma-diagnostic-assay-in-europe 2026-03-26T13:08:13+00:00 hourly 0.9 https://trial.medpath.com/news/vagus-nerve-stimulation-shows-promise-for-ptsd-treatment-in-clinical-trials 2026-03-26T13:07:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vagus-nerve-stimulation-shows-promise-for-ptsd-treatment-in-clinical-trials 2026-03-26T13:07:07+00:00 hourly 0.9 https://trial.medpath.com/news/tonix-pharmaceuticals-initiates-phase-1-study-of-tnx-1900-intranasal-oxytocin-for-migraine-treatment 2026-03-26T13:06:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tonix-pharmaceuticals-initiates-phase-1-study-of-tnx-1900-intranasal-oxytocin-for-migraine-treatment 2026-03-26T13:06:45+00:00 hourly 0.9 https://trial.medpath.com/news/norgine-receives-swiss-approval-for-pedmarqsi-first-treatment-to-prevent-cisplatin-induced-hearing-loss-in-children 2026-03-26T13:04:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/norgine-receives-swiss-approval-for-pedmarqsi-first-treatment-to-prevent-cisplatin-induced-hearing-loss-in-children 2026-03-26T13:04:44+00:00 hourly 0.9 https://trial.medpath.com/news/innate-pharma-advances-oncology-pipeline-with-phase-3-trial-plans-and-promising-adc-data 2026-03-26T09:05:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/innate-pharma-advances-oncology-pipeline-with-phase-3-trial-plans-and-promising-adc-data 2026-03-26T09:05:23+00:00 hourly 0.9 https://trial.medpath.com/news/imperative-care-launches-clear-it-study-to-establish-clinical-standards-for-peripheral-thromboembolism-treatment 2026-03-26T09:04:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/imperative-care-launches-clear-it-study-to-establish-clinical-standards-for-peripheral-thromboembolism-treatment 2026-03-26T09:04:46+00:00 hourly 0.9 https://trial.medpath.com/news/abbvie-and-novartis-mount-legal-challenge-against-illinois-340b-drug-discount-law 2026-03-26T09:04:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/abbvie-and-novartis-mount-legal-challenge-against-illinois-340b-drug-discount-law 2026-03-26T09:04:06+00:00 hourly 0.9 https://trial.medpath.com/news/sk-biopharmaceuticals-launches-cenobamate-in-china-marking-major-milestone-for-epilepsy-treatment 2026-03-26T09:03:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sk-biopharmaceuticals-launches-cenobamate-in-china-marking-major-milestone-for-epilepsy-treatment 2026-03-26T09:03:53+00:00 hourly 0.9 https://trial.medpath.com/news/hmh-holding-completes-210-4-million-ipo-pricing-for-drilling-equipment-technology 2026-03-26T05:08:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hmh-holding-completes-210-4-million-ipo-pricing-for-drilling-equipment-technology 2026-03-26T05:08:01+00:00 hourly 0.9 https://trial.medpath.com/news/purple-biotech-partners-with-converge-bio-to-accelerate-ai-driven-tri-specific-antibody-development 2026-03-26T05:06:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/purple-biotech-partners-with-converge-bio-to-accelerate-ai-driven-tri-specific-antibody-development 2026-03-26T05:06:21+00:00 hourly 0.9 https://trial.medpath.com/news/brightgene-s-oral-glp-1-gip-dual-agonist-bgm0504-shows-promising-weight-loss-results-in-phase-1-trials 2026-03-26T05:05:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/brightgene-s-oral-glp-1-gip-dual-agonist-bgm0504-shows-promising-weight-loss-results-in-phase-1-trials 2026-03-26T05:05:59+00:00 hourly 0.9 https://trial.medpath.com/news/elmed-life-sciences-secures-2-7m-series-a-to-expand-microbiome-based-healthcare-solutions 2026-03-26T05:05:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/elmed-life-sciences-secures-2-7m-series-a-to-expand-microbiome-based-healthcare-solutions 2026-03-26T05:05:55+00:00 hourly 0.9 https://trial.medpath.com/news/helioliver-blood-test-shows-superior-sensitivity-over-ultrasound-for-early-hepatocellular-carcinoma-detection-in-landmark-climb-study 2026-03-26T03:05:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/helioliver-blood-test-shows-superior-sensitivity-over-ultrasound-for-early-hepatocellular-carcinoma-detection-in-landmark-climb-study 2026-03-26T03:05:03+00:00 hourly 0.9 https://trial.medpath.com/news/hrt-patches-show-equal-efficacy-to-injections-for-locally-advanced-prostate-cancer-treatment 2026-03-26T01:07:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hrt-patches-show-equal-efficacy-to-injections-for-locally-advanced-prostate-cancer-treatment 2026-03-26T01:07:19+00:00 hourly 0.9 https://trial.medpath.com/news/flumatinib-therapeutic-drug-monitoring-reveals-key-exposure-thresholds-for-molecular-response-in-chinese-cml-cp-patients 2026-03-26T01:06:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/flumatinib-therapeutic-drug-monitoring-reveals-key-exposure-thresholds-for-molecular-response-in-chinese-cml-cp-patients 2026-03-26T01:06:27+00:00 hourly 0.9 https://trial.medpath.com/news/nugen-medical-devices-advances-needle-free-drug-delivery-with-dual-patent-filings-for-enhanced-injection-technology 2026-03-26T01:06:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nugen-medical-devices-advances-needle-free-drug-delivery-with-dual-patent-filings-for-enhanced-injection-technology 2026-03-26T01:06:07+00:00 hourly 0.9 https://trial.medpath.com/news/methylphenidate-may-reduce-psychosis-risk-in-children-with-adhd-large-finnish-study-shows 2026-03-26T01:05:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/methylphenidate-may-reduce-psychosis-risk-in-children-with-adhd-large-finnish-study-shows 2026-03-26T01:05:39+00:00 hourly 0.9 https://trial.medpath.com/news/breakthrough-oral-drug-delivery-technology-enables-depression-treatment-through-fat-absorption-pathways 2026-03-25T21:07:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/breakthrough-oral-drug-delivery-technology-enables-depression-treatment-through-fat-absorption-pathways 2026-03-25T21:07:22+00:00 hourly 0.9 https://trial.medpath.com/news/blood-pressure-drug-telmisartan-shows-promise-in-enhancing-cancer-treatment-effectiveness 2026-03-25T21:06:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/blood-pressure-drug-telmisartan-shows-promise-in-enhancing-cancer-treatment-effectiveness 2026-03-25T21:06:03+00:00 hourly 0.9 https://trial.medpath.com/news/fish-oil-supplements-show-no-cognitive-benefit-in-alzheimer-s-prevention-usc-study-finds 2026-03-25T21:05:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fish-oil-supplements-show-no-cognitive-benefit-in-alzheimer-s-prevention-usc-study-finds 2026-03-25T21:05:52+00:00 hourly 0.9 https://trial.medpath.com/news/beyondspring-s-plinabulin-shows-promise-in-overcoming-immunotherapy-resistance-in-nsclc 2026-03-25T17:19:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/beyondspring-s-plinabulin-shows-promise-in-overcoming-immunotherapy-resistance-in-nsclc 2026-03-25T17:19:55+00:00 hourly 0.9 https://trial.medpath.com/news/clarity-pharmaceuticals-secures-large-scale-copper-64-manufacturing-agreement-with-theragenics-for-prostate-cancer-diagnostic 2026-03-25T17:05:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/clarity-pharmaceuticals-secures-large-scale-copper-64-manufacturing-agreement-with-theragenics-for-prostate-cancer-diagnostic 2026-03-25T17:05:40+00:00 hourly 0.9 https://trial.medpath.com/news/tropic-biosciences-raises-105-million-series-c-to-scale-gene-edited-tropical-crop-production 2026-03-25T17:05:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tropic-biosciences-raises-105-million-series-c-to-scale-gene-edited-tropical-crop-production 2026-03-25T17:05:34+00:00 hourly 0.9 https://trial.medpath.com/news/scitech-s-st-001-nanofenretinide-shows-early-clinical-benefit-in-cutaneous-t-cell-lymphoma-phase-1a-trial 2026-03-25T17:05:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/scitech-s-st-001-nanofenretinide-shows-early-clinical-benefit-in-cutaneous-t-cell-lymphoma-phase-1a-trial 2026-03-25T17:05:11+00:00 hourly 0.9 https://trial.medpath.com/news/axplora-invests-60-million-in-hpapi-manufacturing-expansion-to-meet-growing-adc-demand 2026-03-25T17:05:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/axplora-invests-60-million-in-hpapi-manufacturing-expansion-to-meet-growing-adc-demand 2026-03-25T17:05:10+00:00 hourly 0.9 https://trial.medpath.com/news/health-canada-approves-apotex-s-clobivis-for-post-cataract-surgery-inflammation-treatment 2026-03-25T17:04:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/health-canada-approves-apotex-s-clobivis-for-post-cataract-surgery-inflammation-treatment 2026-03-25T17:04:52+00:00 hourly 0.9 https://trial.medpath.com/news/sirolimus-eluting-balloons-show-promise-as-alternative-to-permanent-stents-in-heart-attack-treatment 2026-03-25T17:03:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sirolimus-eluting-balloons-show-promise-as-alternative-to-permanent-stents-in-heart-attack-treatment 2026-03-25T17:03:59+00:00 hourly 0.9 https://trial.medpath.com/news/lineage-cell-therapeutics-launches-cor1-cell-therapy-program-to-address-global-corneal-transplant-shortage 2026-03-25T13:11:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lineage-cell-therapeutics-launches-cor1-cell-therapy-program-to-address-global-corneal-transplant-shortage 2026-03-25T13:11:17+00:00 hourly 0.9 https://trial.medpath.com/news/japanese-court-clears-path-for-sawai-s-amitiza-generic-rejecting-viatris-patent-extension-strategy 2026-03-25T13:05:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/japanese-court-clears-path-for-sawai-s-amitiza-generic-rejecting-viatris-patent-extension-strategy 2026-03-25T13:05:42+00:00 hourly 0.9 https://trial.medpath.com/news/cvc-capital-proposes-eur10-9-billion-takeover-of-italian-pharma-recordati 2026-03-25T13:05:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cvc-capital-proposes-eur10-9-billion-takeover-of-italian-pharma-recordati 2026-03-25T13:05:01+00:00 hourly 0.9 https://trial.medpath.com/news/verigraft-initiates-pivotal-phase-ii-iii-trial-for-first-potential-curative-cvi-treatment 2026-03-25T13:04:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/verigraft-initiates-pivotal-phase-ii-iii-trial-for-first-potential-curative-cvi-treatment 2026-03-25T13:04:32+00:00 hourly 0.9 https://trial.medpath.com/news/medtronic-receives-fda-approval-for-expanded-omniasecure-defibrillation-lead-indication 2026-03-25T13:04:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/medtronic-receives-fda-approval-for-expanded-omniasecure-defibrillation-lead-indication 2026-03-25T13:04:24+00:00 hourly 0.9 https://trial.medpath.com/news/mitsui-chemicals-establishes-drug-discovery-lab-in-kentucky-advancing-next-generation-pharmaceutical-materials 2026-03-25T09:03:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mitsui-chemicals-establishes-drug-discovery-lab-in-kentucky-advancing-next-generation-pharmaceutical-materials 2026-03-25T09:03:50+00:00 hourly 0.9 https://trial.medpath.com/news/veeva-systems-acquires-ai-powered-brand-engagement-platform-ostro-for-100-million 2026-03-25T09:03:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/veeva-systems-acquires-ai-powered-brand-engagement-platform-ostro-for-100-million 2026-03-25T09:03:39+00:00 hourly 0.9 https://trial.medpath.com/news/hope-medicine-initiates-phase-iii-trial-for-first-in-class-non-hormonal-endometriosis-treatment 2026-03-25T05:04:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hope-medicine-initiates-phase-iii-trial-for-first-in-class-non-hormonal-endometriosis-treatment 2026-03-25T05:04:43+00:00 hourly 0.9 https://trial.medpath.com/news/absci-s-ai-designed-hair-loss-treatment-abs-201-shows-promising-safety-data-in-phase-1-2a-trial 2026-03-25T01:04:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/absci-s-ai-designed-hair-loss-treatment-abs-201-shows-promising-safety-data-in-phase-1-2a-trial 2026-03-25T01:04:50+00:00 hourly 0.9 https://trial.medpath.com/news/new-cerebrospinal-fluid-biomarker-achieves-94-97-accuracy-in-diagnosing-parkinson-s-disease-and-lewy-body-dementia 2026-03-25T01:04:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/new-cerebrospinal-fluid-biomarker-achieves-94-97-accuracy-in-diagnosing-parkinson-s-disease-and-lewy-body-dementia 2026-03-25T01:04:36+00:00 hourly 0.9 https://trial.medpath.com/news/biolojic-design-s-ai-designed-multibody-tev-325-achieves-preclinical-milestone-for-autoimmune-disease-treatment 2026-03-25T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biolojic-design-s-ai-designed-multibody-tev-325-achieves-preclinical-milestone-for-autoimmune-disease-treatment 2026-03-25T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/20-20-biolabs-partners-with-rokit-healthcare-to-integrate-ckd-prediction-technology-into-longevity-testing-platform 2026-03-24T21:08:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/20-20-biolabs-partners-with-rokit-healthcare-to-integrate-ckd-prediction-technology-into-longevity-testing-platform 2026-03-24T21:08:57+00:00 hourly 0.9 https://trial.medpath.com/news/chinese-researchers-develop-breakthrough-nanoparticle-system-for-scalable-exosome-therapeutic-production 2026-03-24T21:07:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/chinese-researchers-develop-breakthrough-nanoparticle-system-for-scalable-exosome-therapeutic-production 2026-03-24T21:07:58+00:00 hourly 0.9 https://trial.medpath.com/news/recce-pharmaceuticals-advances-phase-3-diabetic-foot-infection-trial-following-clean-indonesian-regulatory-inspection 2026-03-24T21:06:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/recce-pharmaceuticals-advances-phase-3-diabetic-foot-infection-trial-following-clean-indonesian-regulatory-inspection 2026-03-24T21:06:03+00:00 hourly 0.9 https://trial.medpath.com/news/catalyst-pharmaceuticals-settles-firdapse-patent-litigation-with-hetero-labs-securing-market-exclusivity-until-2035 2026-03-24T21:05:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/catalyst-pharmaceuticals-settles-firdapse-patent-litigation-with-hetero-labs-securing-market-exclusivity-until-2035 2026-03-24T21:05:52+00:00 hourly 0.9 https://trial.medpath.com/news/boehringer-ingelheim-advances-dll3-targeting-t-cell-engager-obrixtamig-directly-to-phase-3-first-line-small-cell-lung-cancer-trial 2026-03-24T21:05:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/boehringer-ingelheim-advances-dll3-targeting-t-cell-engager-obrixtamig-directly-to-phase-3-first-line-small-cell-lung-cancer-trial 2026-03-24T21:05:41+00:00 hourly 0.9 https://trial.medpath.com/news/myosin-therapeutics-receives-2-million-florida-grant-for-first-in-human-glioblastoma-trial 2026-03-24T21:05:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/myosin-therapeutics-receives-2-million-florida-grant-for-first-in-human-glioblastoma-trial 2026-03-24T21:05:20+00:00 hourly 0.9 https://trial.medpath.com/news/remegen-s-disitamab-vedotin-receives-fourth-nmpa-approval-for-her2-low-breast-cancer-in-china 2026-03-24T21:05:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/remegen-s-disitamab-vedotin-receives-fourth-nmpa-approval-for-her2-low-breast-cancer-in-china 2026-03-24T21:05:03+00:00 hourly 0.9 https://trial.medpath.com/news/cytiva-partners-with-san-raffaele-institute-to-advance-hematopoietic-stem-cell-gene-therapies 2026-03-24T21:04:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cytiva-partners-with-san-raffaele-institute-to-advance-hematopoietic-stem-cell-gene-therapies 2026-03-24T21:04:50+00:00 hourly 0.9 https://trial.medpath.com/news/italian-drug-approval-reform-shows-mixed-results-on-negotiation-timelines 2026-03-24T21:04:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/italian-drug-approval-reform-shows-mixed-results-on-negotiation-timelines 2026-03-24T21:04:26+00:00 hourly 0.9 https://trial.medpath.com/news/fda-issues-warning-letter-to-immunitybio-over-misleading-cancer-drug-claims-by-patrick-soon-shiong 2026-03-24T21:03:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-issues-warning-letter-to-immunitybio-over-misleading-cancer-drug-claims-by-patrick-soon-shiong 2026-03-24T21:03:49+00:00 hourly 0.9 https://trial.medpath.com/news/28bio-s-cns-3d-brain-organoids-demonstrate-superior-seizure-prediction-accuracy-over-animal-models 2026-03-24T17:17:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/28bio-s-cns-3d-brain-organoids-demonstrate-superior-seizure-prediction-accuracy-over-animal-models 2026-03-24T17:17:16+00:00 hourly 0.9 https://trial.medpath.com/news/achieve-life-sciences-partners-with-adare-pharma-for-cytisinicline-manufacturing-ahead-of-fda-decision 2026-03-24T17:13:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/achieve-life-sciences-partners-with-adare-pharma-for-cytisinicline-manufacturing-ahead-of-fda-decision 2026-03-24T17:13:45+00:00 hourly 0.9 https://trial.medpath.com/news/doctronic-secures-40m-series-b-as-first-ai-system-legally-authorized-to-renew-prescriptions-in-the-u-s 2026-03-24T17:12:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/doctronic-secures-40m-series-b-as-first-ai-system-legally-authorized-to-renew-prescriptions-in-the-u-s 2026-03-24T17:12:13+00:00 hourly 0.9 https://trial.medpath.com/news/apnimed-secures-150m-from-shionogi-joint-venture-sale-advances-first-in-class-osa-drug-toward-fda-submission 2026-03-24T17:11:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/apnimed-secures-150m-from-shionogi-joint-venture-sale-advances-first-in-class-osa-drug-toward-fda-submission 2026-03-24T17:11:52+00:00 hourly 0.9 https://trial.medpath.com/news/major-study-finds-no-link-between-covid-19-vaccines-and-sudden-cardiac-death-in-healthy-young-adults 2026-03-24T17:11:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/major-study-finds-no-link-between-covid-19-vaccines-and-sudden-cardiac-death-in-healthy-young-adults 2026-03-24T17:11:18+00:00 hourly 0.9 https://trial.medpath.com/news/india-launches-world-s-first-clinical-trial-integrating-ayurveda-with-tuberculosis-treatment 2026-03-24T17:11:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/india-launches-world-s-first-clinical-trial-integrating-ayurveda-with-tuberculosis-treatment 2026-03-24T17:11:16+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approved-cancer-drug-doxorubicin-shows-promise-against-drug-resistant-herpes-infections 2026-03-24T17:10:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approved-cancer-drug-doxorubicin-shows-promise-against-drug-resistant-herpes-infections 2026-03-24T17:10:33+00:00 hourly 0.9 https://trial.medpath.com/news/nice-approves-keytruda-as-first-perioperative-immunotherapy-for-head-and-neck-cancer-in-20-years 2026-03-24T17:10:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nice-approves-keytruda-as-first-perioperative-immunotherapy-for-head-and-neck-cancer-in-20-years 2026-03-24T17:10:32+00:00 hourly 0.9 https://trial.medpath.com/news/scotland-launches-first-uk-newborn-screening-program-for-spinal-muscular-atrophy 2026-03-24T17:09:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/scotland-launches-first-uk-newborn-screening-program-for-spinal-muscular-atrophy 2026-03-24T17:09:43+00:00 hourly 0.9 https://trial.medpath.com/news/epifrontier-therapeutics-secures-32m-amed-grant-to-advance-first-in-class-g9a-inhibitor-for-beta-globin-disorders 2026-03-24T17:09:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/epifrontier-therapeutics-secures-32m-amed-grant-to-advance-first-in-class-g9a-inhibitor-for-beta-globin-disorders 2026-03-24T17:09:23+00:00 hourly 0.9 https://trial.medpath.com/news/ra-capital-raises-75m-through-third-spac-targeting-china-based-biotech-companies 2026-03-24T17:09:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ra-capital-raises-75m-through-third-spac-targeting-china-based-biotech-companies 2026-03-24T17:09:21+00:00 hourly 0.9 https://trial.medpath.com/news/intensity-therapeutics-secures-new-us-patent-for-intratumoral-cancer-technology 2026-03-24T17:09:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/intensity-therapeutics-secures-new-us-patent-for-intratumoral-cancer-technology 2026-03-24T17:09:19+00:00 hourly 0.9 https://trial.medpath.com/news/continuity-biosciences-partners-with-breakthrough-t1d-to-advance-novel-cell-therapy-platform-for-type-1-diabetes 2026-03-24T17:09:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/continuity-biosciences-partners-with-breakthrough-t1d-to-advance-novel-cell-therapy-platform-for-type-1-diabetes 2026-03-24T17:09:16+00:00 hourly 0.9 https://trial.medpath.com/news/medtronic-expands-pain-portfolio-with-fda-cleared-viaverte-basivertebral-nerve-ablation-system 2026-03-24T17:09:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/medtronic-expands-pain-portfolio-with-fda-cleared-viaverte-basivertebral-nerve-ablation-system 2026-03-24T17:09:14+00:00 hourly 0.9 https://trial.medpath.com/news/mushrooms-inc-achieves-proof-of-concept-for-mycelium-based-infection-detection-technology 2026-03-24T13:43:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mushrooms-inc-achieves-proof-of-concept-for-mycelium-based-infection-detection-technology 2026-03-24T13:43:00+00:00 hourly 0.9 https://trial.medpath.com/news/callio-therapeutics-initiates-first-in-human-trial-of-dual-payload-adc-clio-8221-for-her2-positive-solid-tumors 2026-03-24T13:10:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/callio-therapeutics-initiates-first-in-human-trial-of-dual-payload-adc-clio-8221-for-her2-positive-solid-tumors 2026-03-24T13:10:32+00:00 hourly 0.9 https://trial.medpath.com/news/dualitybio-achieves-phase-3-success-with-lead-adc-candidate-advances-global-pipeline-across-multiple-cancer-types 2026-03-24T13:10:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dualitybio-achieves-phase-3-success-with-lead-adc-candidate-advances-global-pipeline-across-multiple-cancer-types 2026-03-24T13:10:21+00:00 hourly 0.9 https://trial.medpath.com/news/mana-bio-strengthens-leadership-team-and-prepares-to-present-ai-driven-lnp-data-at-asgct-2026 2026-03-24T13:08:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mana-bio-strengthens-leadership-team-and-prepares-to-present-ai-driven-lnp-data-at-asgct-2026 2026-03-24T13:08:53+00:00 hourly 0.9 https://trial.medpath.com/news/immutrin-secures-87-million-series-a-to-advance-novel-antibody-therapy-for-attr-amyloidosis 2026-03-24T13:08:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/immutrin-secures-87-million-series-a-to-advance-novel-antibody-therapy-for-attr-amyloidosis 2026-03-24T13:08:42+00:00 hourly 0.9 https://trial.medpath.com/news/iaso-bio-receives-japan-pmda-approval-for-phase-iii-car-t-trial-in-earlier-line-multiple-myeloma 2026-03-24T13:06:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/iaso-bio-receives-japan-pmda-approval-for-phase-iii-car-t-trial-in-earlier-line-multiple-myeloma 2026-03-24T13:06:40+00:00 hourly 0.9 https://trial.medpath.com/news/prestige-biopharma-s-hd204-biosimilar-meets-primary-endpoint-in-phase-3-nsclc-trial 2026-03-24T13:06:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/prestige-biopharma-s-hd204-biosimilar-meets-primary-endpoint-in-phase-3-nsclc-trial 2026-03-24T13:06:15+00:00 hourly 0.9 https://trial.medpath.com/news/quotient-therapeutics-partners-with-merck-in-2-2-billion-ibd-drug-discovery-deal-using-somatic-genomics-platform 2026-03-24T13:05:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/quotient-therapeutics-partners-with-merck-in-2-2-billion-ibd-drug-discovery-deal-using-somatic-genomics-platform 2026-03-24T13:05:59+00:00 hourly 0.9 https://trial.medpath.com/news/cortexa-achieves-major-commercial-milestone-with-mdma-supply-in-australia-s-regulated-psychedelic-market 2026-03-24T09:08:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cortexa-achieves-major-commercial-milestone-with-mdma-supply-in-australia-s-regulated-psychedelic-market 2026-03-24T09:08:18+00:00 hourly 0.9 https://trial.medpath.com/news/fresenius-challenges-takeda-s-ibd-drug-patents-in-uk-biosimilar-dispute 2026-03-24T09:06:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fresenius-challenges-takeda-s-ibd-drug-patents-in-uk-biosimilar-dispute 2026-03-24T09:06:19+00:00 hourly 0.9 https://trial.medpath.com/news/kelun-biotech-achieves-breakthrough-in-first-line-nsclc-treatment-with-world-s-first-successful-adc-immunotherapy-combination 2026-03-24T09:05:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kelun-biotech-achieves-breakthrough-in-first-line-nsclc-treatment-with-world-s-first-successful-adc-immunotherapy-combination 2026-03-24T09:05:50+00:00 hourly 0.9 https://trial.medpath.com/news/microbot-medical-launches-full-commercial-release-of-liberty-robotic-system-following-successful-limited-market-adoption 2026-03-24T08:30:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/microbot-medical-launches-full-commercial-release-of-liberty-robotic-system-following-successful-limited-market-adoption 2026-03-24T08:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/pancreatic-cancer-pipeline-reaches-new-milestone-with-200-therapies-from-170-companies-advancing-novel-treatment-approaches 2026-03-24T07:08:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pancreatic-cancer-pipeline-reaches-new-milestone-with-200-therapies-from-170-companies-advancing-novel-treatment-approaches 2026-03-24T07:08:00+00:00 hourly 0.9 https://trial.medpath.com/news/sol-gel-secures-patent-extension-for-patidegib-until-2044-raises-33-1m-to-advance-gorlin-syndrome-trial 2026-03-24T01:58:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sol-gel-secures-patent-extension-for-patidegib-until-2044-raises-33-1m-to-advance-gorlin-syndrome-trial 2026-03-24T01:58:00+00:00 hourly 0.9 https://trial.medpath.com/news/surrozen-advances-wnt-based-retinal-therapeutics-pipeline-plans-ind-filing-for-szn-8141-in-second-half-of-2026 2026-03-24T01:06:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/surrozen-advances-wnt-based-retinal-therapeutics-pipeline-plans-ind-filing-for-szn-8141-in-second-half-of-2026 2026-03-24T01:06:02+00:00 hourly 0.9 https://trial.medpath.com/news/maat-pharma-s-microbiome-therapy-shows-62-response-rate-in-severe-graft-versus-host-disease 2026-03-24T01:05:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/maat-pharma-s-microbiome-therapy-shows-62-response-rate-in-severe-graft-versus-host-disease 2026-03-24T01:05:33+00:00 hourly 0.9 https://trial.medpath.com/news/avalyn-initiates-phase-2-trial-of-inhaled-nintedanib-for-idiopathic-pulmonary-fibrosis 2026-03-24T01:05:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/avalyn-initiates-phase-2-trial-of-inhaled-nintedanib-for-idiopathic-pulmonary-fibrosis 2026-03-24T01:05:32+00:00 hourly 0.9 https://trial.medpath.com/news/celosia-therapeutics-initiates-first-in-human-trial-of-ctx1000-gene-therapy-for-als 2026-03-24T01:05:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/celosia-therapeutics-initiates-first-in-human-trial-of-ctx1000-gene-therapy-for-als 2026-03-24T01:05:30+00:00 hourly 0.9 https://trial.medpath.com/news/cencora-expands-retina-care-network-with-1-1-billion-eyesouth-partners-acquisition 2026-03-24T01:05:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cencora-expands-retina-care-network-with-1-1-billion-eyesouth-partners-acquisition 2026-03-24T01:05:14+00:00 hourly 0.9 https://trial.medpath.com/news/trinity-biotech-s-enhanced-epicapture-test-achieves-85-accuracy-in-prostate-cancer-risk-prediction 2026-03-23T21:08:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/trinity-biotech-s-enhanced-epicapture-test-achieves-85-accuracy-in-prostate-cancer-risk-prediction 2026-03-23T21:08:43+00:00 hourly 0.9 https://trial.medpath.com/news/taiwan-approves-pharmamar-s-zepzelca-combination-as-first-line-maintenance-therapy-for-advanced-small-cell-lung-cancer 2026-03-23T21:05:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/taiwan-approves-pharmamar-s-zepzelca-combination-as-first-line-maintenance-therapy-for-advanced-small-cell-lung-cancer 2026-03-23T21:05:37+00:00 hourly 0.9 https://trial.medpath.com/news/abpi-proposes-nhs-data-integration-to-revitalize-uk-s-declining-clinical-trial-sector 2026-03-23T21:05:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/abpi-proposes-nhs-data-integration-to-revitalize-uk-s-declining-clinical-trial-sector 2026-03-23T21:05:19+00:00 hourly 0.9 https://trial.medpath.com/news/quantum-biopharma-s-unbuzzd-supplement-shows-significant-alcohol-metabolism-acceleration-in-peer-reviewed-clinical-trial 2026-03-23T17:15:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/quantum-biopharma-s-unbuzzd-supplement-shows-significant-alcohol-metabolism-acceleration-in-peer-reviewed-clinical-trial 2026-03-23T17:15:08+00:00 hourly 0.9 https://trial.medpath.com/news/bausch-lomb-s-elios-system-achieves-primary-endpoints-in-24-month-u-s-glaucoma-trial 2026-03-23T17:13:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bausch-lomb-s-elios-system-achieves-primary-endpoints-in-24-month-u-s-glaucoma-trial 2026-03-23T17:13:20+00:00 hourly 0.9 https://trial.medpath.com/news/sintx-technologies-achieves-first-human-implant-of-fda-cleared-silicon-nitride-foot-and-ankle-device 2026-03-23T17:13:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sintx-technologies-achieves-first-human-implant-of-fda-cleared-silicon-nitride-foot-and-ankle-device 2026-03-23T17:13:04+00:00 hourly 0.9 https://trial.medpath.com/news/kraig-biocraft-laboratories-scales-spider-silk-production-with-new-facility-and-enhanced-r-d-capacity 2026-03-23T17:12:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kraig-biocraft-laboratories-scales-spider-silk-production-with-new-facility-and-enhanced-r-d-capacity 2026-03-23T17:12:57+00:00 hourly 0.9 https://trial.medpath.com/news/roche-opens-institute-of-human-biology-in-basel-with-chf-1-4-billion-investment-to-revolutionize-drug-discovery 2026-03-23T17:11:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/roche-opens-institute-of-human-biology-in-basel-with-chf-1-4-billion-investment-to-revolutionize-drug-discovery 2026-03-23T17:11:08+00:00 hourly 0.9 https://trial.medpath.com/news/viatris-secures-first-ever-gad-treatment-approval-in-japan-with-effexor 2026-03-23T17:09:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/viatris-secures-first-ever-gad-treatment-approval-in-japan-with-effexor 2026-03-23T17:09:52+00:00 hourly 0.9 https://trial.medpath.com/news/german-court-grants-sales-ban-for-generic-fampridine-products-following-patent-victory-for-merz 2026-03-23T17:09:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/german-court-grants-sales-ban-for-generic-fampridine-products-following-patent-victory-for-merz 2026-03-23T17:09:40+00:00 hourly 0.9 https://trial.medpath.com/news/bio-thera-solutions-expands-partnership-with-intas-for-golimumab-biosimilar-bat2506-in-india 2026-03-23T17:09:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bio-thera-solutions-expands-partnership-with-intas-for-golimumab-biosimilar-bat2506-in-india 2026-03-23T17:09:39+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-priority-review-to-zilganersen-for-alexander-disease-setting-stage-for-first-treatment 2026-03-23T17:09:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-priority-review-to-zilganersen-for-alexander-disease-setting-stage-for-first-treatment 2026-03-23T17:09:38+00:00 hourly 0.9 https://trial.medpath.com/news/godavari-biorefineries-secures-japanese-patent-for-novel-v-atpase-inhibitor-antiviral-compounds 2026-03-23T17:08:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/godavari-biorefineries-secures-japanese-patent-for-novel-v-atpase-inhibitor-antiviral-compounds 2026-03-23T17:08:50+00:00 hourly 0.9 https://trial.medpath.com/news/apollo-acquires-37-stake-in-syntegon-as-pharmaceutical-packaging-giant-eyes-north-american-expansion 2026-03-23T17:08:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/apollo-acquires-37-stake-in-syntegon-as-pharmaceutical-packaging-giant-eyes-north-american-expansion 2026-03-23T17:08:20+00:00 hourly 0.9 https://trial.medpath.com/news/stealth-biotherapeutics-secures-mrc-grant-to-advance-sbt-589-for-leigh-syndrome-treatment 2026-03-23T17:07:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/stealth-biotherapeutics-secures-mrc-grant-to-advance-sbt-589-for-leigh-syndrome-treatment 2026-03-23T17:07:33+00:00 hourly 0.9 https://trial.medpath.com/news/shionogi-completes-2-5-billion-acquisition-of-radicava-for-als-treatment-expanding-rare-disease-portfolio 2026-03-23T17:07:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/shionogi-completes-2-5-billion-acquisition-of-radicava-for-als-treatment-expanding-rare-disease-portfolio 2026-03-23T17:07:31+00:00 hourly 0.9 https://trial.medpath.com/news/enlivex-receives-fda-ind-clearance-for-phase-2b-trial-of-allocetra-in-age-related-knee-osteoarthritis 2026-03-23T17:07:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/enlivex-receives-fda-ind-clearance-for-phase-2b-trial-of-allocetra-in-age-related-knee-osteoarthritis 2026-03-23T17:07:24+00:00 hourly 0.9 https://trial.medpath.com/news/inmed-s-inm-901-shows-promise-in-human-brain-organoid-models-for-alzheimer-s-disease-treatment 2026-03-23T17:07:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/inmed-s-inm-901-shows-promise-in-human-brain-organoid-models-for-alzheimer-s-disease-treatment 2026-03-23T17:07:22+00:00 hourly 0.9 https://trial.medpath.com/news/glyconex-partners-with-nippon-kayaku-to-develop-tumor-activated-adc-gnx201-for-solid-tumors 2026-03-23T17:06:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/glyconex-partners-with-nippon-kayaku-to-develop-tumor-activated-adc-gnx201-for-solid-tumors 2026-03-23T17:06:54+00:00 hourly 0.9 https://trial.medpath.com/news/ondine-s-steriwave-phase-3-trial-reaches-93-enrollment-milestone-in-landmark-surgical-site-infection-prevention-study 2026-03-23T17:06:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ondine-s-steriwave-phase-3-trial-reaches-93-enrollment-milestone-in-landmark-surgical-site-infection-prevention-study 2026-03-23T17:06:18+00:00 hourly 0.9 https://trial.medpath.com/news/biocytogen-partners-with-moonlight-bio-to-develop-advanced-cell-therapies-for-difficult-to-treat-cancers 2026-03-23T17:05:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biocytogen-partners-with-moonlight-bio-to-develop-advanced-cell-therapies-for-difficult-to-treat-cancers 2026-03-23T17:05:10+00:00 hourly 0.9 https://trial.medpath.com/news/chugai-receives-world-first-approval-for-lunsumio-polivy-combination-in-relapsed-large-b-cell-lymphoma 2026-03-23T13:21:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/chugai-receives-world-first-approval-for-lunsumio-polivy-combination-in-relapsed-large-b-cell-lymphoma 2026-03-23T13:21:35+00:00 hourly 0.9 https://trial.medpath.com/news/karmanos-cancer-institute-becomes-first-independent-cancer-center-to-offer-hemophilia-b-gene-therapy 2026-03-23T13:21:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/karmanos-cancer-institute-becomes-first-independent-cancer-center-to-offer-hemophilia-b-gene-therapy 2026-03-23T13:21:34+00:00 hourly 0.9 https://trial.medpath.com/news/biolinerx-advances-glix1-glioblastoma-trial-as-company-reports-2025-financial-results 2026-03-23T13:21:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biolinerx-advances-glix1-glioblastoma-trial-as-company-reports-2025-financial-results 2026-03-23T13:21:33+00:00 hourly 0.9 https://trial.medpath.com/news/endocyclic-therapeutics-receives-fda-ind-clearance-for-first-in-class-non-hormonal-endometriosis-treatment-endo-205 2026-03-23T13:18:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/endocyclic-therapeutics-receives-fda-ind-clearance-for-first-in-class-non-hormonal-endometriosis-treatment-endo-205 2026-03-23T13:18:30+00:00 hourly 0.9 https://trial.medpath.com/news/laigo-bio-secures-eur17m-in-oversubscribed-seed-round-to-advance-novel-protein-degradation-platform 2026-03-23T13:18:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/laigo-bio-secures-eur17m-in-oversubscribed-seed-round-to-advance-novel-protein-degradation-platform 2026-03-23T13:18:28+00:00 hourly 0.9 https://trial.medpath.com/news/abbott-completes-21-billion-exact-sciences-acquisition-while-novartis-invests-2-billion-in-next-generation-pi3ka-inhibitors 2026-03-23T13:17:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/abbott-completes-21-billion-exact-sciences-acquisition-while-novartis-invests-2-billion-in-next-generation-pi3ka-inhibitors 2026-03-23T13:17:42+00:00 hourly 0.9 https://trial.medpath.com/news/just-evotec-biologics-secures-10m-barda-contract-to-optimize-filovirus-antibody-manufacturing 2026-03-23T13:17:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/just-evotec-biologics-secures-10m-barda-contract-to-optimize-filovirus-antibody-manufacturing 2026-03-23T13:17:21+00:00 hourly 0.9 https://trial.medpath.com/news/brain-biotech-secures-european-patent-for-novel-crispr-bmc-genome-editing-technology 2026-03-23T13:16:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/brain-biotech-secures-european-patent-for-novel-crispr-bmc-genome-editing-technology 2026-03-23T13:16:53+00:00 hourly 0.9 https://trial.medpath.com/news/pfizer-and-valneva-s-lyme-disease-vaccine-shows-73-efficacy-in-phase-3-trial 2026-03-23T13:16:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pfizer-and-valneva-s-lyme-disease-vaccine-shows-73-efficacy-in-phase-3-trial 2026-03-23T13:16:51+00:00 hourly 0.9 https://trial.medpath.com/news/fecal-microbiota-transplantation-shows-promise-for-severe-c-difficile-infections-despite-regulatory-challenges 2026-03-23T13:16:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fecal-microbiota-transplantation-shows-promise-for-severe-c-difficile-infections-despite-regulatory-challenges 2026-03-23T13:16:49+00:00 hourly 0.9 https://trial.medpath.com/news/ema-grants-orphan-drug-status-to-uab-s-maresin-1-therapy-for-spinal-cord-injuries 2026-03-23T13:16:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ema-grants-orphan-drug-status-to-uab-s-maresin-1-therapy-for-spinal-cord-injuries 2026-03-23T13:16:40+00:00 hourly 0.9 https://trial.medpath.com/news/pfizer-valneva-lyme-disease-vaccine-shows-73-efficacy-but-faces-regulatory-hurdle-after-missing-statistical-endpoint 2026-03-23T13:16:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pfizer-valneva-lyme-disease-vaccine-shows-73-efficacy-but-faces-regulatory-hurdle-after-missing-statistical-endpoint 2026-03-23T13:16:04+00:00 hourly 0.9 https://trial.medpath.com/news/indian-courts-strengthen-patent-opposition-framework-in-high-profile-cancer-immunotherapy-and-drug-delivery-cases 2026-03-23T09:07:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/indian-courts-strengthen-patent-opposition-framework-in-high-profile-cancer-immunotherapy-and-drug-delivery-cases 2026-03-23T09:07:33+00:00 hourly 0.9 https://trial.medpath.com/news/contezolid-shows-superior-safety-profile-to-linezolid-in-real-world-treatment-of-drug-resistant-infections 2026-03-23T09:06:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/contezolid-shows-superior-safety-profile-to-linezolid-in-real-world-treatment-of-drug-resistant-infections 2026-03-23T09:06:17+00:00 hourly 0.9 https://trial.medpath.com/news/monash-university-and-clinchoice-form-strategic-partnership-to-accelerate-early-phase-clinical-trials 2026-03-23T09:05:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/monash-university-and-clinchoice-form-strategic-partnership-to-accelerate-early-phase-clinical-trials 2026-03-23T09:05:16+00:00 hourly 0.9 https://trial.medpath.com/news/hypersomnia-pipeline-advances-with-novel-therapies-from-avadel-zevra-and-alkermes 2026-03-23T07:08:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hypersomnia-pipeline-advances-with-novel-therapies-from-avadel-zevra-and-alkermes 2026-03-23T07:08:00+00:00 hourly 0.9 https://trial.medpath.com/news/cleo-diagnostics-expands-ovarian-cancer-test-biomarker-panel-to-eight-markers-ahead-of-fda-submission 2026-03-23T05:06:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cleo-diagnostics-expands-ovarian-cancer-test-biomarker-panel-to-eight-markers-ahead-of-fda-submission 2026-03-23T05:06:51+00:00 hourly 0.9 https://trial.medpath.com/news/innovent-biologics-initiates-phase-3-trial-for-novel-gout-drug-tigulixostat-in-china 2026-03-23T05:05:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/innovent-biologics-initiates-phase-3-trial-for-novel-gout-drug-tigulixostat-in-china 2026-03-23T05:05:56+00:00 hourly 0.9 https://trial.medpath.com/news/harbour-biomed-s-tslp-targeting-antibody-hbm9378-shows-favorable-safety-profile-in-phase-i-trial 2026-03-23T05:05:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/harbour-biomed-s-tslp-targeting-antibody-hbm9378-shows-favorable-safety-profile-in-phase-i-trial 2026-03-23T05:05:39+00:00 hourly 0.9 https://trial.medpath.com/news/digital-pcr-outperforms-standard-rt-qpcr-in-detecting-residual-bcr-abl1-in-cml-patients-enabling-better-tki-discontinuation-decisions 2026-03-23T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/digital-pcr-outperforms-standard-rt-qpcr-in-detecting-residual-bcr-abl1-in-cml-patients-enabling-better-tki-discontinuation-decisions 2026-03-23T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/pepsico-analyst-targets-fluctuate-as-company-pursues-price-cuts-and-health-focused-product-pipeline-for-2026-turnaround 2026-03-22T21:06:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pepsico-analyst-targets-fluctuate-as-company-pursues-price-cuts-and-health-focused-product-pipeline-for-2026-turnaround 2026-03-22T21:06:06+00:00 hourly 0.9 https://trial.medpath.com/news/cdsco-expert-panel-mandates-protocol-revisions-for-glimepiride-linagliptin-combination-phase-iii-trial 2026-03-22T21:06:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cdsco-expert-panel-mandates-protocol-revisions-for-glimepiride-linagliptin-combination-phase-iii-trial 2026-03-22T21:06:03+00:00 hourly 0.9 https://trial.medpath.com/news/hepatitis-c-drug-bemnifosbuvir-shows-promise-against-hepatitis-e-virus-in-preclinical-studies 2026-03-22T21:05:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hepatitis-c-drug-bemnifosbuvir-shows-promise-against-hepatitis-e-virus-in-preclinical-studies 2026-03-22T21:05:55+00:00 hourly 0.9 https://trial.medpath.com/news/vesicor-therapeutics-appoints-michael-tolentino-as-ceo-to-lead-p53-based-cancer-therapy-development 2026-03-22T17:05:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vesicor-therapeutics-appoints-michael-tolentino-as-ceo-to-lead-p53-based-cancer-therapy-development 2026-03-22T17:05:03+00:00 hourly 0.9 https://trial.medpath.com/news/pfizer-s-comirnaty-vaccine-transitions-to-endemic-phase-with-sustained-european-market-presence 2026-03-22T13:04:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pfizer-s-comirnaty-vaccine-transitions-to-endemic-phase-with-sustained-european-market-presence 2026-03-22T13:04:59+00:00 hourly 0.9 https://trial.medpath.com/news/siemens-healthineers-partners-with-imaginostics-to-advance-quantitative-mri-technology-for-magnetom-systems 2026-03-22T13:04:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/siemens-healthineers-partners-with-imaginostics-to-advance-quantitative-mri-technology-for-magnetom-systems 2026-03-22T13:04:51+00:00 hourly 0.9 https://trial.medpath.com/news/clariant-establishes-first-us-manufacturing-site-for-pharmaceutical-grade-peg-excipients-in-texas 2026-03-22T01:04:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/clariant-establishes-first-us-manufacturing-site-for-pharmaceutical-grade-peg-excipients-in-texas 2026-03-22T01:04:22+00:00 hourly 0.9 https://trial.medpath.com/news/tg-therapeutics-secures-500-million-credit-facility-to-fuel-briumvi-growth-and-pipeline-development 2026-03-21T21:07:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tg-therapeutics-secures-500-million-credit-facility-to-fuel-briumvi-growth-and-pipeline-development 2026-03-21T21:07:17+00:00 hourly 0.9 https://trial.medpath.com/news/spyre-therapeutics-completes-phase-1-safety-study-of-spy001-001-advancing-early-stage-pipeline 2026-03-21T21:05:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/spyre-therapeutics-completes-phase-1-safety-study-of-spy001-001-advancing-early-stage-pipeline 2026-03-21T21:05:00+00:00 hourly 0.9 https://trial.medpath.com/news/akums-launches-world-s-first-lasmiditan-dispersible-tablets-for-acute-migraine-treatment 2026-03-21T21:04:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/akums-launches-world-s-first-lasmiditan-dispersible-tablets-for-acute-migraine-treatment 2026-03-21T21:04:47+00:00 hourly 0.9 https://trial.medpath.com/news/zegfrovy-achieves-primary-endpoint-in-phase-3-trial-for-first-line-egfr-exon-20-insertion-nsclc 2026-03-21T17:05:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/zegfrovy-achieves-primary-endpoint-in-phase-3-trial-for-first-line-egfr-exon-20-insertion-nsclc 2026-03-21T17:05:45+00:00 hourly 0.9 https://trial.medpath.com/news/fda-mandates-seizure-risk-warnings-for-parkinson-s-drugs-containing-carbidopa-and-levodopa 2026-03-21T13:10:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-mandates-seizure-risk-warnings-for-parkinson-s-drugs-containing-carbidopa-and-levodopa 2026-03-21T13:10:03+00:00 hourly 0.9 https://trial.medpath.com/news/curi-bio-launches-curiversetm-platform-to-scale-3d-human-tissue-models-for-industrial-drug-discovery 2026-03-21T01:08:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/curi-bio-launches-curiversetm-platform-to-scale-3d-human-tissue-models-for-industrial-drug-discovery 2026-03-21T01:08:05+00:00 hourly 0.9 https://trial.medpath.com/news/fda-clears-varian-truebeam-systems-for-low-dose-radiation-therapy-in-osteoarthritis 2026-03-21T01:07:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-clears-varian-truebeam-systems-for-low-dose-radiation-therapy-in-osteoarthritis 2026-03-21T01:07:39+00:00 hourly 0.9 https://trial.medpath.com/news/incyte-to-present-long-term-povorcitinib-data-for-hidradenitis-suppurativa-at-aad-2026 2026-03-21T01:06:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/incyte-to-present-long-term-povorcitinib-data-for-hidradenitis-suppurativa-at-aad-2026 2026-03-21T01:06:04+00:00 hourly 0.9 https://trial.medpath.com/news/thermo-fisher-scientific-completes-8-9-billion-clario-acquisition-to-strengthen-clinical-trial-capabilities 2026-03-21T01:05:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/thermo-fisher-scientific-completes-8-9-billion-clario-acquisition-to-strengthen-clinical-trial-capabilities 2026-03-21T01:05:22+00:00 hourly 0.9 https://trial.medpath.com/news/large-clinical-trial-shows-behavioral-hydration-program-fails-to-reduce-kidney-stone-recurrence-despite-smart-bottle-technology 2026-03-21T01:04:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/large-clinical-trial-shows-behavioral-hydration-program-fails-to-reduce-kidney-stone-recurrence-despite-smart-bottle-technology 2026-03-21T01:04:52+00:00 hourly 0.9 https://trial.medpath.com/news/smart-hydrogel-wound-dressing-delivers-antibiotics-on-demand-to-combat-resistance 2026-03-20T19:59:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/smart-hydrogel-wound-dressing-delivers-antibiotics-on-demand-to-combat-resistance 2026-03-20T19:59:00+00:00 hourly 0.9 https://trial.medpath.com/news/leo-pharma-presents-real-world-evidence-for-dermatology-portfolio-at-aad-2026 2026-03-20T17:14:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/leo-pharma-presents-real-world-evidence-for-dermatology-portfolio-at-aad-2026 2026-03-20T17:14:08+00:00 hourly 0.9 https://trial.medpath.com/news/lab-grown-oesophagus-successfully-restores-swallowing-function-in-pigs-human-trials-planned-within-five-years 2026-03-20T17:09:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lab-grown-oesophagus-successfully-restores-swallowing-function-in-pigs-human-trials-planned-within-five-years 2026-03-20T17:09:46+00:00 hourly 0.9 https://trial.medpath.com/news/biodesix-publishes-largest-lung-nodule-biomarker-validation-study-supporting-earlier-cancer-detection 2026-03-20T17:09:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biodesix-publishes-largest-lung-nodule-biomarker-validation-study-supporting-earlier-cancer-detection 2026-03-20T17:09:08+00:00 hourly 0.9 https://trial.medpath.com/news/arch-biopartners-advances-lsalt-peptide-phase-ii-trial-for-cardiac-surgery-associated-acute-kidney-injury 2026-03-20T17:07:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/arch-biopartners-advances-lsalt-peptide-phase-ii-trial-for-cardiac-surgery-associated-acute-kidney-injury 2026-03-20T17:07:30+00:00 hourly 0.9 https://trial.medpath.com/news/mixed-results-from-cardiac-resynchronization-trials-challenge-left-bundle-branch-pacing-as-biv-alternative 2026-03-20T15:11:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mixed-results-from-cardiac-resynchronization-trials-challenge-left-bundle-branch-pacing-as-biv-alternative 2026-03-20T15:11:00+00:00 hourly 0.9 https://trial.medpath.com/news/boehringer-ingelheim-partners-with-emfret-analytics-to-advance-novel-gpvi-inhibitor-ema601-for-stroke-treatment 2026-03-20T12:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/boehringer-ingelheim-partners-with-emfret-analytics-to-advance-novel-gpvi-inhibitor-ema601-for-stroke-treatment 2026-03-20T12:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/novartis-acquires-next-generation-pi3ka-inhibitor-snv4818-in-3-billion-deal-to-strengthen-breast-cancer-pipeline 2026-03-20T10:45:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novartis-acquires-next-generation-pi3ka-inhibitor-snv4818-in-3-billion-deal-to-strengthen-breast-cancer-pipeline 2026-03-20T10:45:28+00:00 hourly 0.9 https://trial.medpath.com/news/bio-sourcing-and-tiny-cargo-partner-to-develop-first-oral-monoclonal-antibody-platform-using-goat-milk-exosomes 2026-03-20T05:10:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bio-sourcing-and-tiny-cargo-partner-to-develop-first-oral-monoclonal-antibody-platform-using-goat-milk-exosomes 2026-03-20T05:10:04+00:00 hourly 0.9 https://trial.medpath.com/news/lunai-bioworks-launches-national-chemical-defense-consortium-with-ai-driven-3-year-antidote-development-model 2026-03-20T05:09:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lunai-bioworks-launches-national-chemical-defense-consortium-with-ai-driven-3-year-antidote-development-model 2026-03-20T05:09:11+00:00 hourly 0.9 https://trial.medpath.com/news/verily-secures-300-million-investment-and-gains-independence-from-alphabet-to-advance-ai-driven-precision-health-platform 2026-03-20T05:09:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/verily-secures-300-million-investment-and-gains-independence-from-alphabet-to-advance-ai-driven-precision-health-platform 2026-03-20T05:09:10+00:00 hourly 0.9 https://trial.medpath.com/news/mayo-clinic-pilot-study-demonstrates-safe-home-based-chemotherapy-delivery 2026-03-20T05:08:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mayo-clinic-pilot-study-demonstrates-safe-home-based-chemotherapy-delivery 2026-03-20T05:08:59+00:00 hourly 0.9 https://trial.medpath.com/news/adalta-completes-global-patent-protection-for-anti-fibrotic-drug-ad-214-with-canadian-approval 2026-03-20T05:07:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/adalta-completes-global-patent-protection-for-anti-fibrotic-drug-ad-214-with-canadian-approval 2026-03-20T05:07:34+00:00 hourly 0.9 https://trial.medpath.com/news/nice-ordered-to-reconsider-alzheimer-s-drugs-after-successful-appeals-by-eli-lilly-and-eisai 2026-03-20T05:05:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nice-ordered-to-reconsider-alzheimer-s-drugs-after-successful-appeals-by-eli-lilly-and-eisai 2026-03-20T05:05:52+00:00 hourly 0.9 https://trial.medpath.com/news/6th-mrna-based-therapeutics-summit-returns-to-boston-with-focus-on-ai-driven-design-in-vivo-cell-engineering-and-global-regulatory-harmonization 2026-03-20T03:53:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/6th-mrna-based-therapeutics-summit-returns-to-boston-with-focus-on-ai-driven-design-in-vivo-cell-engineering-and-global-regulatory-harmonization 2026-03-20T03:53:14+00:00 hourly 0.9 https://trial.medpath.com/news/curis-reports-promising-mrd-conversion-data-for-emavusertib-in-aml-combination-therapy 2026-03-20T01:58:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/curis-reports-promising-mrd-conversion-data-for-emavusertib-in-aml-combination-therapy 2026-03-20T01:58:03+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-first-blood-test-for-colorectal-cancer-screening-as-american-cancer-society-updates-guidelines 2026-03-19T21:31:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-first-blood-test-for-colorectal-cancer-screening-as-american-cancer-society-updates-guidelines 2026-03-19T21:31:00+00:00 hourly 0.9 https://trial.medpath.com/news/collegium-pharmaceutical-acquires-azstarys-for-650-million-to-strengthen-adhd-portfolio 2026-03-19T21:14:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/collegium-pharmaceutical-acquires-azstarys-for-650-million-to-strengthen-adhd-portfolio 2026-03-19T21:14:32+00:00 hourly 0.9 https://trial.medpath.com/news/ac-immune-achieves-first-in-vivo-imaging-of-tdp-43-brain-pathology-with-novel-pet-tracer-aci-19626 2026-03-19T21:12:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ac-immune-achieves-first-in-vivo-imaging-of-tdp-43-brain-pathology-with-novel-pet-tracer-aci-19626 2026-03-19T21:12:28+00:00 hourly 0.9 https://trial.medpath.com/news/context-therapeutics-advances-t-cell-engager-pipeline-with-three-bispecific-antibodies-in-clinical-development 2026-03-19T21:11:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/context-therapeutics-advances-t-cell-engager-pipeline-with-three-bispecific-antibodies-in-clinical-development 2026-03-19T21:11:10+00:00 hourly 0.9 https://trial.medpath.com/news/triana-biomedicines-tri-611-receives-fda-fast-track-designation-for-alk-nsclc-treatment 2026-03-19T21:10:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/triana-biomedicines-tri-611-receives-fda-fast-track-designation-for-alk-nsclc-treatment 2026-03-19T21:10:07+00:00 hourly 0.9 https://trial.medpath.com/news/experimental-hookworm-vaccine-demonstrates-significant-protection-in-phase-2-human-trial 2026-03-19T21:08:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/experimental-hookworm-vaccine-demonstrates-significant-protection-in-phase-2-human-trial 2026-03-19T21:08:11+00:00 hourly 0.9 https://trial.medpath.com/news/glaukos-launches-first-fda-approved-epithelium-on-corneal-cross-linking-treatment-for-keratoconus-in-us 2026-03-19T21:04:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/glaukos-launches-first-fda-approved-epithelium-on-corneal-cross-linking-treatment-for-keratoconus-in-us 2026-03-19T21:04:57+00:00 hourly 0.9 https://trial.medpath.com/news/sarepta-therapeutics-seeks-traditional-approval-for-duchenne-muscular-dystrophy-therapies-following-fda-feedback 2026-03-19T17:14:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sarepta-therapeutics-seeks-traditional-approval-for-duchenne-muscular-dystrophy-therapies-following-fda-feedback 2026-03-19T17:14:35+00:00 hourly 0.9 https://trial.medpath.com/news/convergent-therapeutics-to-present-phase-2-data-for-conv01-a-in-lu-psma-pretreated-metastatic-prostate-cancer-at-asco-2026 2026-03-19T17:12:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/convergent-therapeutics-to-present-phase-2-data-for-conv01-a-in-lu-psma-pretreated-metastatic-prostate-cancer-at-asco-2026 2026-03-19T17:12:57+00:00 hourly 0.9 https://trial.medpath.com/news/embecta-acquires-owen-mumford-for-ps150-million-to-expand-drug-delivery-platform-capabilities 2026-03-19T17:12:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/embecta-acquires-owen-mumford-for-ps150-million-to-expand-drug-delivery-platform-capabilities 2026-03-19T17:12:49+00:00 hourly 0.9 https://trial.medpath.com/news/altesa-biosciences-vapendavir-shows-first-ever-activity-against-rhinovirus-c-in-breakthrough-research 2026-03-19T17:10:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/altesa-biosciences-vapendavir-shows-first-ever-activity-against-rhinovirus-c-in-breakthrough-research 2026-03-19T17:10:14+00:00 hourly 0.9 https://trial.medpath.com/news/car-t-cell-therapy-shows-early-promise-in-progressive-multiple-sclerosis-first-patients-treated-in-pioneering-trials 2026-03-19T17:09:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/car-t-cell-therapy-shows-early-promise-in-progressive-multiple-sclerosis-first-patients-treated-in-pioneering-trials 2026-03-19T17:09:16+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-fast-track-designation-to-remix-therapeutics-rem-422-for-adenoid-cystic-carcinoma-treatment 2026-03-19T17:09:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-fast-track-designation-to-remix-therapeutics-rem-422-for-adenoid-cystic-carcinoma-treatment 2026-03-19T17:09:14+00:00 hourly 0.9 https://trial.medpath.com/news/annovis-bio-partners-with-neurorpm-to-deploy-ai-powered-digital-biomarker-technology-in-parkinson-s-disease-clinical-trial 2026-03-19T17:09:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/annovis-bio-partners-with-neurorpm-to-deploy-ai-powered-digital-biomarker-technology-in-parkinson-s-disease-clinical-trial 2026-03-19T17:09:05+00:00 hourly 0.9 https://trial.medpath.com/news/pfizer-s-talzenna-shows-significant-benefit-in-hormone-sensitive-prostate-cancer-trial 2026-03-19T17:07:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pfizer-s-talzenna-shows-significant-benefit-in-hormone-sensitive-prostate-cancer-trial 2026-03-19T17:07:55+00:00 hourly 0.9 https://trial.medpath.com/news/pharmamar-partners-with-globant-to-deploy-ai-powered-drug-discovery-platform-achieving-15x-faster-cancer-research-insights 2026-03-19T17:06:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pharmamar-partners-with-globant-to-deploy-ai-powered-drug-discovery-platform-achieving-15x-faster-cancer-research-insights 2026-03-19T17:06:28+00:00 hourly 0.9 https://trial.medpath.com/news/lytix-biopharma-reports-promising-phase-ii-data-for-ruxotemitide-in-advanced-melanoma-and-triple-negative-breast-cancer 2026-03-19T17:06:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lytix-biopharma-reports-promising-phase-ii-data-for-ruxotemitide-in-advanced-melanoma-and-triple-negative-breast-cancer 2026-03-19T17:06:25+00:00 hourly 0.9 https://trial.medpath.com/news/fda-digital-health-leader-signals-forthcoming-updates-to-artificial-intelligence-policy 2026-03-19T17:06:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-digital-health-leader-signals-forthcoming-updates-to-artificial-intelligence-policy 2026-03-19T17:06:18+00:00 hourly 0.9 https://trial.medpath.com/news/providence-medical-technology-launches-superiority-trial-for-corus-lx-lumbar-fusion-system 2026-03-19T17:05:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/providence-medical-technology-launches-superiority-trial-for-corus-lx-lumbar-fusion-system 2026-03-19T17:05:29+00:00 hourly 0.9 https://trial.medpath.com/news/cytosorbents-launches-hotswaptm-technology-and-reports-positive-clinical-data-for-blood-purification-therapy 2026-03-19T17:05:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cytosorbents-launches-hotswaptm-technology-and-reports-positive-clinical-data-for-blood-purification-therapy 2026-03-19T17:05:28+00:00 hourly 0.9 https://trial.medpath.com/news/livanova-s-aura6000-system-receives-fda-approval-for-obstructive-sleep-apnea-treatment 2026-03-19T17:05:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/livanova-s-aura6000-system-receives-fda-approval-for-obstructive-sleep-apnea-treatment 2026-03-19T17:05:26+00:00 hourly 0.9 https://trial.medpath.com/news/chemomab-secures-fda-alignment-for-phase-3-trial-of-nebokitug-in-primary-sclerosing-cholangitis 2026-03-19T14:45:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/chemomab-secures-fda-alignment-for-phase-3-trial-of-nebokitug-in-primary-sclerosing-cholangitis 2026-03-19T14:45:48+00:00 hourly 0.9 https://trial.medpath.com/news/python-derived-metabolite-shows-promise-as-novel-weight-loss-drug-with-reduced-side-effects 2026-03-19T14:45:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/python-derived-metabolite-shows-promise-as-novel-weight-loss-drug-with-reduced-side-effects 2026-03-19T14:45:36+00:00 hourly 0.9 https://trial.medpath.com/news/sk-pharmteco-commits-100-million-to-strengthen-viral-vector-manufacturing-capabilities 2026-03-19T14:45:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sk-pharmteco-commits-100-million-to-strengthen-viral-vector-manufacturing-capabilities 2026-03-19T14:45:19+00:00 hourly 0.9 https://trial.medpath.com/news/lupin-manufacturing-solutions-expands-dabhasa-facility-to-scale-peptide-and-adc-manufacturing-capabilities 2026-03-19T14:44:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lupin-manufacturing-solutions-expands-dabhasa-facility-to-scale-peptide-and-adc-manufacturing-capabilities 2026-03-19T14:44:38+00:00 hourly 0.9 https://trial.medpath.com/news/evotec-and-bristol-myers-squibb-advance-novel-molecular-glue-degrader-bms-986506-into-phase-1-trial-for-kidney-cancer 2026-03-19T14:44:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/evotec-and-bristol-myers-squibb-advance-novel-molecular-glue-degrader-bms-986506-into-phase-1-trial-for-kidney-cancer 2026-03-19T14:44:12+00:00 hourly 0.9 https://trial.medpath.com/news/eight-week-probiotic-trial-shows-promise-for-functional-gastrointestinal-disorders-in-placebo-controlled-study 2026-03-19T14:44:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eight-week-probiotic-trial-shows-promise-for-functional-gastrointestinal-disorders-in-placebo-controlled-study 2026-03-19T14:44:05+00:00 hourly 0.9 https://trial.medpath.com/news/belief-biomed-s-gene-therapy-bbm-h901-receives-approval-in-macao-for-hemophilia-b-treatment 2026-03-19T14:44:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/belief-biomed-s-gene-therapy-bbm-h901-receives-approval-in-macao-for-hemophilia-b-treatment 2026-03-19T14:44:02+00:00 hourly 0.9 https://trial.medpath.com/news/chugai-files-regulatory-application-for-revolutionary-port-delivery-platform-in-japan 2026-03-19T14:44:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/chugai-files-regulatory-application-for-revolutionary-port-delivery-platform-in-japan 2026-03-19T14:44:00+00:00 hourly 0.9 https://trial.medpath.com/news/aspen-neuroscience-s-personalized-parkinson-s-cell-therapy-shows-promise-in-phase-ii-trial-advances-to-pivotal-study 2026-03-19T14:42:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aspen-neuroscience-s-personalized-parkinson-s-cell-therapy-shows-promise-in-phase-ii-trial-advances-to-pivotal-study 2026-03-19T14:42:00+00:00 hourly 0.9 https://trial.medpath.com/news/chinese-scientists-develop-revolutionary-mitochondrial-transplantation-therapy-for-parkinson-s-disease-and-genetic-disorders 2026-03-19T11:14:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/chinese-scientists-develop-revolutionary-mitochondrial-transplantation-therapy-for-parkinson-s-disease-and-genetic-disorders 2026-03-19T11:14:00+00:00 hourly 0.9 https://trial.medpath.com/news/al-s-pharma-s-ap-101-shows-clinically-meaningful-disease-modification-and-prolonged-survival-in-als-phase-2-trial 2026-03-19T09:04:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/al-s-pharma-s-ap-101-shows-clinically-meaningful-disease-modification-and-prolonged-survival-in-als-phase-2-trial 2026-03-19T09:04:41+00:00 hourly 0.9 https://trial.medpath.com/news/shionogi-initiates-phase-2-trial-for-first-oral-substrate-reduction-therapy-in-late-onset-pompe-disease 2026-03-19T09:04:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/shionogi-initiates-phase-2-trial-for-first-oral-substrate-reduction-therapy-in-late-onset-pompe-disease 2026-03-19T09:04:06+00:00 hourly 0.9 https://trial.medpath.com/news/trisalus-publishes-preclinical-data-showing-enhanced-tumor-delivery-and-immune-activation-with-pedd-delivered-nelitolimod 2026-03-19T05:05:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/trisalus-publishes-preclinical-data-showing-enhanced-tumor-delivery-and-immune-activation-with-pedd-delivered-nelitolimod 2026-03-19T05:05:10+00:00 hourly 0.9 https://trial.medpath.com/news/guardant-health-advances-multi-product-growth-strategy-with-quest-partnership-and-fda-milestones 2026-03-19T01:05:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/guardant-health-advances-multi-product-growth-strategy-with-quest-partnership-and-fda-milestones 2026-03-19T01:05:29+00:00 hourly 0.9 https://trial.medpath.com/news/argentina-repeals-restrictive-pharmaceutical-patent-guidelines-sparking-industry-debate-over-generic-drug-access 2026-03-19T01:04:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/argentina-repeals-restrictive-pharmaceutical-patent-guidelines-sparking-industry-debate-over-generic-drug-access 2026-03-19T01:04:34+00:00 hourly 0.9 https://trial.medpath.com/news/first-michigan-patient-successfully-receives-fda-approved-sickle-cell-gene-therapy-lyfgenia 2026-03-19T01:04:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/first-michigan-patient-successfully-receives-fda-approved-sickle-cell-gene-therapy-lyfgenia 2026-03-19T01:04:27+00:00 hourly 0.9 https://trial.medpath.com/news/louisiana-man-becomes-first-in-southeast-to-receive-gene-therapy-for-sickle-cell-disease 2026-03-19T01:04:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/louisiana-man-becomes-first-in-southeast-to-receive-gene-therapy-for-sickle-cell-disease 2026-03-19T01:04:24+00:00 hourly 0.9 https://trial.medpath.com/news/aptamer-group-launches-radiopharmaceutical-program-with-enhanced-stability-profile 2026-03-19T01:03:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aptamer-group-launches-radiopharmaceutical-program-with-enhanced-stability-profile 2026-03-19T01:03:55+00:00 hourly 0.9 https://trial.medpath.com/news/pattern-computer-secures-global-patent-protection-for-ai-discovered-triple-negative-breast-cancer-therapy-pci020302 2026-03-18T21:09:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pattern-computer-secures-global-patent-protection-for-ai-discovered-triple-negative-breast-cancer-therapy-pci020302 2026-03-18T21:09:59+00:00 hourly 0.9 https://trial.medpath.com/news/kupando-raises-eur10-million-to-advance-dual-tlr-agonist-kup101-into-phase-1b-clinical-trial 2026-03-18T21:09:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kupando-raises-eur10-million-to-advance-dual-tlr-agonist-kup101-into-phase-1b-clinical-trial 2026-03-18T21:09:09+00:00 hourly 0.9 https://trial.medpath.com/news/artelo-biosciences-enters-16-3-billion-glaucoma-market-with-fully-funded-clinical-trial-of-art27-13 2026-03-18T21:07:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/artelo-biosciences-enters-16-3-billion-glaucoma-market-with-fully-funded-clinical-trial-of-art27-13 2026-03-18T21:07:12+00:00 hourly 0.9 https://trial.medpath.com/news/volitionrx-achieves-breakthrough-in-liquid-biopsy-with-99-pure-cancer-dna-isolation 2026-03-18T21:06:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/volitionrx-achieves-breakthrough-in-liquid-biopsy-with-99-pure-cancer-dna-isolation 2026-03-18T21:06:43+00:00 hourly 0.9 https://trial.medpath.com/news/diakonos-oncology-to-present-first-in-class-doc1021-dendritic-cell-therapy-data-at-major-cancer-conferences 2026-03-18T21:05:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/diakonos-oncology-to-present-first-in-class-doc1021-dendritic-cell-therapy-data-at-major-cancer-conferences 2026-03-18T21:05:55+00:00 hourly 0.9 https://trial.medpath.com/news/superstring-capital-management-invests-6-84-million-in-cns-drug-developer-axsome-therapeutics 2026-03-18T21:05:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/superstring-capital-management-invests-6-84-million-in-cns-drug-developer-axsome-therapeutics 2026-03-18T21:05:48+00:00 hourly 0.9 https://trial.medpath.com/news/multi-strain-probiotic-shows-promise-in-reducing-bacterial-vaginosis-recurrence 2026-03-18T21:05:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/multi-strain-probiotic-shows-promise-in-reducing-bacterial-vaginosis-recurrence 2026-03-18T21:05:38+00:00 hourly 0.9 https://trial.medpath.com/news/us-appeals-court-revives-false-claims-lawsuit-against-four-pharma-giants-over-340b-drug-pricing-violations 2026-03-18T21:05:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/us-appeals-court-revives-false-claims-lawsuit-against-four-pharma-giants-over-340b-drug-pricing-violations 2026-03-18T21:05:33+00:00 hourly 0.9 https://trial.medpath.com/news/mindera-health-and-mountaineer-biosciences-launch-subtilitas-platform-for-precision-dermatology-research 2026-03-18T21:04:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mindera-health-and-mountaineer-biosciences-launch-subtilitas-platform-for-precision-dermatology-research 2026-03-18T21:04:44+00:00 hourly 0.9 https://trial.medpath.com/news/nia-therapeutics-receives-fda-breakthrough-device-designation-for-ai-guided-brain-implant-to-treat-tbi-related-memory-loss 2026-03-18T21:04:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nia-therapeutics-receives-fda-breakthrough-device-designation-for-ai-guided-brain-implant-to-treat-tbi-related-memory-loss 2026-03-18T21:04:43+00:00 hourly 0.9 https://trial.medpath.com/news/dod-awards-11m-for-novel-ulcerative-colitis-trial-combining-biologic-with-plant-based-nutraceutical 2026-03-18T21:04:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dod-awards-11m-for-novel-ulcerative-colitis-trial-combining-biologic-with-plant-based-nutraceutical 2026-03-18T21:04:01+00:00 hourly 0.9 https://trial.medpath.com/news/new-england-biolabs-and-touchlight-launch-cell-free-dna-synthesis-kit-to-accelerate-gene-therapy-development 2026-03-18T17:09:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/new-england-biolabs-and-touchlight-launch-cell-free-dna-synthesis-kit-to-accelerate-gene-therapy-development 2026-03-18T17:09:00+00:00 hourly 0.9 https://trial.medpath.com/news/crossbow-therapeutics-secures-77-million-series-b-to-advance-tcr-mimetic-cancer-immunotherapies 2026-03-18T17:08:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/crossbow-therapeutics-secures-77-million-series-b-to-advance-tcr-mimetic-cancer-immunotherapies 2026-03-18T17:08:30+00:00 hourly 0.9 https://trial.medpath.com/news/jenavalve-s-trilogy-system-becomes-first-fda-approved-tavr-device-for-severe-aortic-regurgitation 2026-03-18T17:07:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/jenavalve-s-trilogy-system-becomes-first-fda-approved-tavr-device-for-severe-aortic-regurgitation 2026-03-18T17:07:54+00:00 hourly 0.9 https://trial.medpath.com/news/first-validated-biomarker-transforms-hormone-therapy-decisions-in-recurrent-prostate-cancer 2026-03-18T17:07:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/first-validated-biomarker-transforms-hormone-therapy-decisions-in-recurrent-prostate-cancer 2026-03-18T17:07:18+00:00 hourly 0.9 https://trial.medpath.com/news/atrogi-doses-first-patients-in-phase-1-trial-of-exercise-mimicking-drug-atr-258 2026-03-18T17:07:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/atrogi-doses-first-patients-in-phase-1-trial-of-exercise-mimicking-drug-atr-258 2026-03-18T17:07:15+00:00 hourly 0.9 https://trial.medpath.com/news/triplet-therapy-doubles-survival-in-her2-positive-breast-cancer-patients-with-leptomeningeal-metastasis 2026-03-18T17:07:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/triplet-therapy-doubles-survival-in-her2-positive-breast-cancer-patients-with-leptomeningeal-metastasis 2026-03-18T17:07:13+00:00 hourly 0.9 https://trial.medpath.com/news/trinity-biotech-partners-with-university-at-buffalo-to-develop-novel-sjogren-s-syndrome-biomarkers 2026-03-18T17:07:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/trinity-biotech-partners-with-university-at-buffalo-to-develop-novel-sjogren-s-syndrome-biomarkers 2026-03-18T17:07:12+00:00 hourly 0.9 https://trial.medpath.com/news/excalipoint-therapeutics-secures-68-7-million-in-seed-funding-to-advance-next-generation-t-cell-engager-pipeline 2026-03-18T17:06:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/excalipoint-therapeutics-secures-68-7-million-in-seed-funding-to-advance-next-generation-t-cell-engager-pipeline 2026-03-18T17:06:57+00:00 hourly 0.9 https://trial.medpath.com/news/merit-medical-launches-resilience-tts-esophageal-stent-for-cancer-related-strictures-and-fistulas 2026-03-18T15:01:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/merit-medical-launches-resilience-tts-esophageal-stent-for-cancer-related-strictures-and-fistulas 2026-03-18T15:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/eco-innovation-group-acquires-kepler-gtl-s-patent-portfolio-for-sustainable-aviation-fuel-production 2026-03-18T14:05:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eco-innovation-group-acquires-kepler-gtl-s-patent-portfolio-for-sustainable-aviation-fuel-production 2026-03-18T14:05:00+00:00 hourly 0.9 https://trial.medpath.com/news/duke-researchers-develop-nasal-swab-test-for-early-alzheimer-s-detection 2026-03-18T13:05:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/duke-researchers-develop-nasal-swab-test-for-early-alzheimer-s-detection 2026-03-18T13:05:30+00:00 hourly 0.9 https://trial.medpath.com/news/sanofi-commits-180m-for-kali-s-novel-trispecific-antibody-in-autoimmune-disease-partnership 2026-03-18T12:39:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sanofi-commits-180m-for-kali-s-novel-trispecific-antibody-in-autoimmune-disease-partnership 2026-03-18T12:39:00+00:00 hourly 0.9 https://trial.medpath.com/news/biotheryx-advances-btx-9341-cdk4-6-degrader-into-dose-expansion-phase-for-hr-her2-breast-cancer 2026-03-18T11:58:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biotheryx-advances-btx-9341-cdk4-6-degrader-into-dose-expansion-phase-for-hr-her2-breast-cancer 2026-03-18T11:58:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-authorizes-first-non-tobacco-flavored-e-cigarettes-with-advanced-age-gating-technology 2026-03-18T09:06:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-authorizes-first-non-tobacco-flavored-e-cigarettes-with-advanced-age-gating-technology 2026-03-18T09:06:18+00:00 hourly 0.9 https://trial.medpath.com/news/vietnam-approves-first-enterovirus-a71-vaccine-as-mvc-and-substipharm-target-southeast-asian-expansion 2026-03-18T09:05:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vietnam-approves-first-enterovirus-a71-vaccine-as-mvc-and-substipharm-target-southeast-asian-expansion 2026-03-18T09:05:36+00:00 hourly 0.9 https://trial.medpath.com/news/university-of-sheffield-receives-ps1m-grant-to-develop-smart-gel-drug-delivery-system-for-glioblastoma 2026-03-18T05:04:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/university-of-sheffield-receives-ps1m-grant-to-develop-smart-gel-drug-delivery-system-for-glioblastoma 2026-03-18T05:04:49+00:00 hourly 0.9 https://trial.medpath.com/news/silexion-therapeutics-receives-israeli-regulatory-approval-for-phase-2-3-trial-of-kras-targeting-rnai-therapy-sil204 2026-03-18T01:10:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/silexion-therapeutics-receives-israeli-regulatory-approval-for-phase-2-3-trial-of-kras-targeting-rnai-therapy-sil204 2026-03-18T01:10:02+00:00 hourly 0.9 https://trial.medpath.com/news/akamis-bio-s-ng-350a-shows-50-response-rate-in-locally-advanced-rectal-cancer-phase-1b-trial 2026-03-18T01:08:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/akamis-bio-s-ng-350a-shows-50-response-rate-in-locally-advanced-rectal-cancer-phase-1b-trial 2026-03-18T01:08:39+00:00 hourly 0.9 https://trial.medpath.com/news/gsk-ends-flovent-monopoly-after-senate-investigation-reveals-367-million-medicaid-rebate-avoidance 2026-03-18T01:08:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gsk-ends-flovent-monopoly-after-senate-investigation-reveals-367-million-medicaid-rebate-avoidance 2026-03-18T01:08:38+00:00 hourly 0.9 https://trial.medpath.com/news/zymeworks-advances-novel-ras-targeting-adc-platform-with-clinical-data-from-zw191-at-aacr-2026 2026-03-18T01:07:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/zymeworks-advances-novel-ras-targeting-adc-platform-with-clinical-data-from-zw191-at-aacr-2026 2026-03-18T01:07:04+00:00 hourly 0.9 https://trial.medpath.com/news/immunitas-therapeutics-to-present-first-in-human-data-for-novel-anti-cd161-antibody-imt-009-at-aacr-2026 2026-03-18T01:06:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/immunitas-therapeutics-to-present-first-in-human-data-for-novel-anti-cd161-antibody-imt-009-at-aacr-2026 2026-03-18T01:06:55+00:00 hourly 0.9 https://trial.medpath.com/news/blossomhill-therapeutics-unveils-next-generation-pan-kras-inhibitors-with-picomolar-potency-at-aacr-2026 2026-03-18T01:06:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/blossomhill-therapeutics-unveils-next-generation-pan-kras-inhibitors-with-picomolar-potency-at-aacr-2026 2026-03-18T01:06:50+00:00 hourly 0.9 https://trial.medpath.com/news/delhi-high-court-orders-patent-office-to-resolve-novartis-breast-cancer-drug-application-after-13-year-delay 2026-03-18T01:05:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/delhi-high-court-orders-patent-office-to-resolve-novartis-breast-cancer-drug-application-after-13-year-delay 2026-03-18T01:05:54+00:00 hourly 0.9 https://trial.medpath.com/news/peijia-medical-s-dcwire-micro-guidewire-receives-first-fda-510-k-clearance-opening-u-s-market-entry 2026-03-18T01:05:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/peijia-medical-s-dcwire-micro-guidewire-receives-first-fda-510-k-clearance-opening-u-s-market-entry 2026-03-18T01:05:18+00:00 hourly 0.9 https://trial.medpath.com/news/verismo-therapeutics-reports-first-clinical-data-for-novel-multi-chain-kir-car-therapies-at-aacr-2026 2026-03-18T01:05:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/verismo-therapeutics-reports-first-clinical-data-for-novel-multi-chain-kir-car-therapies-at-aacr-2026 2026-03-18T01:05:02+00:00 hourly 0.9 https://trial.medpath.com/news/sionna-therapeutics-advances-cftr-modulators-for-cystic-fibrosis-with-strong-analyst-support-and-summer-data-readouts 2026-03-18T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sionna-therapeutics-advances-cftr-modulators-for-cystic-fibrosis-with-strong-analyst-support-and-summer-data-readouts 2026-03-18T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/abbott-and-exact-sciences-present-breakthrough-multi-cancer-early-detection-data-at-aacr-2026 2026-03-17T21:31:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/abbott-and-exact-sciences-present-breakthrough-multi-cancer-early-detection-data-at-aacr-2026 2026-03-17T21:31:00+00:00 hourly 0.9 https://trial.medpath.com/news/r1-therapeutics-launches-with-77-5-million-series-a-to-develop-novel-chronic-kidney-disease-treatment 2026-03-17T21:07:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/r1-therapeutics-launches-with-77-5-million-series-a-to-develop-novel-chronic-kidney-disease-treatment 2026-03-17T21:07:42+00:00 hourly 0.9 https://trial.medpath.com/news/act-capital-management-invests-8-million-in-tg-therapeutics-despite-30-stock-decline 2026-03-17T21:07:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/act-capital-management-invests-8-million-in-tg-therapeutics-despite-30-stock-decline 2026-03-17T21:07:31+00:00 hourly 0.9 https://trial.medpath.com/news/first-european-real-world-analysis-validates-immunowell-jcv-test-for-pml-risk-assessment-in-multiple-sclerosis-patients 2026-03-17T21:06:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/first-european-real-world-analysis-validates-immunowell-jcv-test-for-pml-risk-assessment-in-multiple-sclerosis-patients 2026-03-17T21:06:44+00:00 hourly 0.9 https://trial.medpath.com/news/caribou-biosciences-allogeneic-car-t-therapy-shows-promising-durability-data-in-latest-clinical-update 2026-03-17T21:06:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/caribou-biosciences-allogeneic-car-t-therapy-shows-promising-durability-data-in-latest-clinical-update 2026-03-17T21:06:39+00:00 hourly 0.9 https://trial.medpath.com/news/northwestern-scientists-discover-fructose-metabolism-pathway-drives-glioblastoma-growth-and-immune-suppression 2026-03-17T21:06:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/northwestern-scientists-discover-fructose-metabolism-pathway-drives-glioblastoma-growth-and-immune-suppression 2026-03-17T21:06:07+00:00 hourly 0.9 https://trial.medpath.com/news/sino-biopharmaceutical-receives-nmpa-approval-for-first-in-class-osteoarthritis-drug-trd221-clinical-trial 2026-03-17T21:05:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sino-biopharmaceutical-receives-nmpa-approval-for-first-in-class-osteoarthritis-drug-trd221-clinical-trial 2026-03-17T21:05:23+00:00 hourly 0.9 https://trial.medpath.com/news/egypt-and-takeda-pharmaceutical-strengthen-research-partnership-to-advance-clinical-trials-and-drug-access 2026-03-17T21:05:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/egypt-and-takeda-pharmaceutical-strengthen-research-partnership-to-advance-clinical-trials-and-drug-access 2026-03-17T21:05:16+00:00 hourly 0.9 https://trial.medpath.com/news/long-term-follow-up-data-confirm-sustained-survival-benefits-of-pd-1-inhibitors-in-nasopharyngeal-and-esophageal-cancers 2026-03-17T21:05:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/long-term-follow-up-data-confirm-sustained-survival-benefits-of-pd-1-inhibitors-in-nasopharyngeal-and-esophageal-cancers 2026-03-17T21:05:14+00:00 hourly 0.9 https://trial.medpath.com/news/nice-suspends-resminostat-appraisal-after-company-withdraws-marketing-authorization-application 2026-03-17T21:05:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nice-suspends-resminostat-appraisal-after-company-withdraws-marketing-authorization-application 2026-03-17T21:05:00+00:00 hourly 0.9 https://trial.medpath.com/news/merck-reports-long-term-hpv-vaccine-efficacy-data-spanning-up-to-18-years 2026-03-17T21:04:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/merck-reports-long-term-hpv-vaccine-efficacy-data-spanning-up-to-18-years 2026-03-17T21:04:35+00:00 hourly 0.9 https://trial.medpath.com/news/uc-berkeley-researchers-develop-machine-learning-methods-to-accelerate-drug-development-using-real-world-evidence 2026-03-17T21:03:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/uc-berkeley-researchers-develop-machine-learning-methods-to-accelerate-drug-development-using-real-world-evidence 2026-03-17T21:03:57+00:00 hourly 0.9 https://trial.medpath.com/news/cellprothera-advances-protheracytes-stem-cell-therapy-to-phase-iii-for-post-mi-heart-failure 2026-03-17T21:03:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cellprothera-advances-protheracytes-stem-cell-therapy-to-phase-iii-for-post-mi-heart-failure 2026-03-17T21:03:53+00:00 hourly 0.9 https://trial.medpath.com/news/asimov-partners-with-score-pharma-to-develop-enhanced-anti-her2-antibody-therapeutics-for-breast-cancer 2026-03-17T17:22:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/asimov-partners-with-score-pharma-to-develop-enhanced-anti-her2-antibody-therapeutics-for-breast-cancer 2026-03-17T17:22:00+00:00 hourly 0.9 https://trial.medpath.com/news/voro-therapeutics-partners-with-daiichi-sankyo-to-develop-tumor-activated-adcs-using-primebody-platform 2026-03-17T17:13:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/voro-therapeutics-partners-with-daiichi-sankyo-to-develop-tumor-activated-adcs-using-primebody-platform 2026-03-17T17:13:39+00:00 hourly 0.9 https://trial.medpath.com/news/grifols-chronos-platform-detects-parkinson-s-disease-biomarkers-up-to-12-years-before-clinical-diagnosis 2026-03-17T17:12:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/grifols-chronos-platform-detects-parkinson-s-disease-biomarkers-up-to-12-years-before-clinical-diagnosis 2026-03-17T17:12:19+00:00 hourly 0.9 https://trial.medpath.com/news/spago-nanomedical-s-177lu-sn201-shows-continued-safety-in-phase-i-iia-trial-across-multiple-solid-tumors 2026-03-17T17:11:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/spago-nanomedical-s-177lu-sn201-shows-continued-safety-in-phase-i-iia-trial-across-multiple-solid-tumors 2026-03-17T17:11:22+00:00 hourly 0.9 https://trial.medpath.com/news/avance-clinical-appoints-liahna-toy-to-lead-global-early-phase-center-of-excellence 2026-03-17T17:10:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/avance-clinical-appoints-liahna-toy-to-lead-global-early-phase-center-of-excellence 2026-03-17T17:10:36+00:00 hourly 0.9 https://trial.medpath.com/news/vst-bio-secures-45m-series-a-to-advance-first-in-class-stroke-therapeutic-vb-001-into-human-trials 2026-03-17T17:10:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vst-bio-secures-45m-series-a-to-advance-first-in-class-stroke-therapeutic-vb-001-into-human-trials 2026-03-17T17:10:09+00:00 hourly 0.9 https://trial.medpath.com/news/taiwan-bio-partners-with-terumo-to-automate-regulatory-t-cell-manufacturing-for-transplant-therapy 2026-03-17T17:09:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/taiwan-bio-partners-with-terumo-to-automate-regulatory-t-cell-manufacturing-for-transplant-therapy 2026-03-17T17:09:33+00:00 hourly 0.9 https://trial.medpath.com/news/osm-car-t-therapy-shows-promise-against-osteosarcoma-in-preclinical-studies 2026-03-17T17:09:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/osm-car-t-therapy-shows-promise-against-osteosarcoma-in-preclinical-studies 2026-03-17T17:09:30+00:00 hourly 0.9 https://trial.medpath.com/news/alzpath-s-ptau217-antibody-gains-widespread-validation-at-ad-pd-2026-conference 2026-03-17T17:09:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/alzpath-s-ptau217-antibody-gains-widespread-validation-at-ad-pd-2026-conference 2026-03-17T17:09:05+00:00 hourly 0.9 https://trial.medpath.com/news/idel-therapeutics-raises-eur9-million-to-advance-direct-cytosolic-drug-delivery-platform-for-cancer-treatment 2026-03-17T17:08:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/idel-therapeutics-raises-eur9-million-to-advance-direct-cytosolic-drug-delivery-platform-for-cancer-treatment 2026-03-17T17:08:27+00:00 hourly 0.9 https://trial.medpath.com/news/liminatus-pharma-plans-phase-1-trial-of-iba101-cd47-blocking-antibody-for-lung-cancer 2026-03-17T17:08:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/liminatus-pharma-plans-phase-1-trial-of-iba101-cd47-blocking-antibody-for-lung-cancer 2026-03-17T17:08:25+00:00 hourly 0.9 https://trial.medpath.com/news/innorna-receives-fda-clearance-for-first-in-class-mrna-therapy-in026-targeting-refractory-gout 2026-03-17T17:06:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/innorna-receives-fda-clearance-for-first-in-class-mrna-therapy-in026-targeting-refractory-gout 2026-03-17T17:06:31+00:00 hourly 0.9 https://trial.medpath.com/news/start-partners-with-trialing-to-expand-access-to-oncology-clinical-trials-across-europe 2026-03-17T17:04:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/start-partners-with-trialing-to-expand-access-to-oncology-clinical-trials-across-europe 2026-03-17T17:04:47+00:00 hourly 0.9 https://trial.medpath.com/news/fda-rejects-aldeyra-s-dry-eye-disease-drug-reproxalap-for-third-time-citing-insufficient-efficacy 2026-03-17T17:04:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-rejects-aldeyra-s-dry-eye-disease-drug-reproxalap-for-third-time-citing-insufficient-efficacy 2026-03-17T17:04:44+00:00 hourly 0.9 https://trial.medpath.com/news/researchers-uncover-how-lecanemab-activates-brain-s-immune-cells-to-clear-alzheimer-s-plaques 2026-03-17T17:04:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/researchers-uncover-how-lecanemab-activates-brain-s-immune-cells-to-clear-alzheimer-s-plaques 2026-03-17T17:04:41+00:00 hourly 0.9 https://trial.medpath.com/news/pixelgen-technologies-partners-with-karolinska-institutet-to-discover-novel-biomarkers-for-cancer-immunotherapy-response 2026-03-17T13:07:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pixelgen-technologies-partners-with-karolinska-institutet-to-discover-novel-biomarkers-for-cancer-immunotherapy-response 2026-03-17T13:07:20+00:00 hourly 0.9 https://trial.medpath.com/news/landmark-review-finds-no-evidence-of-medicinal-cannabis-efficacy-for-major-mental-health-disorders 2026-03-17T13:05:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/landmark-review-finds-no-evidence-of-medicinal-cannabis-efficacy-for-major-mental-health-disorders 2026-03-17T13:05:39+00:00 hourly 0.9 https://trial.medpath.com/news/immupharma-secures-ps7-5m-funding-to-advance-kapiglucagon-for-type-1-diabetes-artificial-pancreas-systems 2026-03-17T13:05:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/immupharma-secures-ps7-5m-funding-to-advance-kapiglucagon-for-type-1-diabetes-artificial-pancreas-systems 2026-03-17T13:05:27+00:00 hourly 0.9 https://trial.medpath.com/news/crism-therapeutics-secures-fda-orphan-drug-designation-for-brain-cancer-treatment 2026-03-17T13:05:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/crism-therapeutics-secures-fda-orphan-drug-designation-for-brain-cancer-treatment 2026-03-17T13:05:20+00:00 hourly 0.9 https://trial.medpath.com/news/sequential-secures-3-5m-to-develop-ai-powered-platform-for-skin-health-biomarker-discovery 2026-03-17T13:05:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sequential-secures-3-5m-to-develop-ai-powered-platform-for-skin-health-biomarker-discovery 2026-03-17T13:05:13+00:00 hourly 0.9 https://trial.medpath.com/news/outrun-therapeutics-advances-first-in-class-e6ap-inhibitor-for-hpv-positive-head-and-neck-cancer 2026-03-17T13:05:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/outrun-therapeutics-advances-first-in-class-e6ap-inhibitor-for-hpv-positive-head-and-neck-cancer 2026-03-17T13:05:12+00:00 hourly 0.9 https://trial.medpath.com/news/merck-presents-positive-phase-3-data-for-oral-pcsk9-inhibitor-enlicitide-at-acc-26 2026-03-17T13:04:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/merck-presents-positive-phase-3-data-for-oral-pcsk9-inhibitor-enlicitide-at-acc-26 2026-03-17T13:04:56+00:00 hourly 0.9 https://trial.medpath.com/news/r1-therapeutics-launches-with-77-5m-to-develop-novel-kidney-disease-treatment 2026-03-17T13:04:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/r1-therapeutics-launches-with-77-5m-to-develop-novel-kidney-disease-treatment 2026-03-17T13:04:52+00:00 hourly 0.9 https://trial.medpath.com/news/soley-therapeutics-develops-first-in-class-ckap2-modulator-stx-6398-for-cancer-treatment 2026-03-17T10:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/soley-therapeutics-develops-first-in-class-ckap2-modulator-stx-6398-for-cancer-treatment 2026-03-17T10:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/iron-mediated-ferroptosis-impairs-car-t-cell-function-and-antitumor-efficacy-in-multiple-myeloma 2026-03-17T09:03:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/iron-mediated-ferroptosis-impairs-car-t-cell-function-and-antitumor-efficacy-in-multiple-myeloma 2026-03-17T09:03:19+00:00 hourly 0.9 https://trial.medpath.com/news/lightbridge-secures-key-patent-approvals-for-advanced-nuclear-fuel-technology-in-canada-and-europe 2026-03-17T08:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lightbridge-secures-key-patent-approvals-for-advanced-nuclear-fuel-technology-in-canada-and-europe 2026-03-17T08:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/jamp-pharma-group-launches-generic-enzalutamide-for-prostate-cancer-treatment-in-canada 2026-03-17T05:05:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/jamp-pharma-group-launches-generic-enzalutamide-for-prostate-cancer-treatment-in-canada 2026-03-17T05:05:03+00:00 hourly 0.9 https://trial.medpath.com/news/england-launches-one-off-menb-vaccination-programme-for-students-ahead-of-2026-academic-year 2026-03-17T03:32:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/england-launches-one-off-menb-vaccination-programme-for-students-ahead-of-2026-academic-year 2026-03-17T03:32:31+00:00 hourly 0.9 https://trial.medpath.com/news/scientists-engineer-bacteria-to-transform-plastic-waste-into-parkinson-s-drug-l-dopa 2026-03-17T01:07:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/scientists-engineer-bacteria-to-transform-plastic-waste-into-parkinson-s-drug-l-dopa 2026-03-17T01:07:27+00:00 hourly 0.9 https://trial.medpath.com/news/dual-drug-combinations-show-promise-in-overcoming-multiple-myeloma-resistance 2026-03-17T01:07:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dual-drug-combinations-show-promise-in-overcoming-multiple-myeloma-resistance 2026-03-17T01:07:02+00:00 hourly 0.9 https://trial.medpath.com/news/pyc-therapeutics-advances-two-rna-based-therapies-for-inherited-blindness-conditions 2026-03-17T01:06:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pyc-therapeutics-advances-two-rna-based-therapies-for-inherited-blindness-conditions 2026-03-17T01:06:39+00:00 hourly 0.9 https://trial.medpath.com/news/novartis-completes-11-billion-bond-sale-to-finance-avidity-biosciences-acquisition 2026-03-17T01:06:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novartis-completes-11-billion-bond-sale-to-finance-avidity-biosciences-acquisition 2026-03-17T01:06:34+00:00 hourly 0.9 https://trial.medpath.com/news/ibio-advances-bispecific-antibody-for-pulmonary-hypertension-in-heart-failure-targets-q3-2026-development-candidate 2026-03-17T01:06:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ibio-advances-bispecific-antibody-for-pulmonary-hypertension-in-heart-failure-targets-q3-2026-development-candidate 2026-03-17T01:06:31+00:00 hourly 0.9 https://trial.medpath.com/news/aptar-s-intranasal-delivery-system-advances-ltr-pharma-s-spontan-phase-ii-trial-for-erectile-dysfunction 2026-03-17T01:05:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aptar-s-intranasal-delivery-system-advances-ltr-pharma-s-spontan-phase-ii-trial-for-erectile-dysfunction 2026-03-17T01:05:28+00:00 hourly 0.9 https://trial.medpath.com/news/gnq-insilico-to-go-public-through-500m-spac-deal-advancing-ai-powered-drug-development-platforms 2026-03-17T01:05:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gnq-insilico-to-go-public-through-500m-spac-deal-advancing-ai-powered-drug-development-platforms 2026-03-17T01:05:24+00:00 hourly 0.9 https://trial.medpath.com/news/glenmark-announces-us-launch-of-potassium-phosphates-injection-for-hypophosphatemia-treatment 2026-03-17T01:04:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/glenmark-announces-us-launch-of-potassium-phosphates-injection-for-hypophosphatemia-treatment 2026-03-17T01:04:38+00:00 hourly 0.9 https://trial.medpath.com/news/datatrak-and-tailrd-heart-form-strategic-partnership-to-advance-ai-driven-cardiovascular-clinical-research 2026-03-17T01:04:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/datatrak-and-tailrd-heart-form-strategic-partnership-to-advance-ai-driven-cardiovascular-clinical-research 2026-03-17T01:04:35+00:00 hourly 0.9 https://trial.medpath.com/news/metis-techbio-debuts-on-hong-kong-exchange-as-world-s-first-publicly-listed-ai-powered-drug-delivery-company 2026-03-16T23:59:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/metis-techbio-debuts-on-hong-kong-exchange-as-world-s-first-publicly-listed-ai-powered-drug-delivery-company 2026-03-16T23:59:00+00:00 hourly 0.9 https://trial.medpath.com/news/briohealth-reaches-100-briovad-implants-gains-fda-approval-for-pediatric-heart-failure-trial 2026-03-16T23:59:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/briohealth-reaches-100-briovad-implants-gains-fda-approval-for-pediatric-heart-failure-trial 2026-03-16T23:59:00+00:00 hourly 0.9 https://trial.medpath.com/news/bulgold-closes-1-17-million-private-placement-to-advance-slovak-gold-project-development 2026-03-16T22:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bulgold-closes-1-17-million-private-placement-to-advance-slovak-gold-project-development 2026-03-16T22:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/solve-gne-advances-first-gene-therapy-for-gne-myopathy-toward-phase-i-clinical-trial 2026-03-16T21:09:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/solve-gne-advances-first-gene-therapy-for-gne-myopathy-toward-phase-i-clinical-trial 2026-03-16T21:09:33+00:00 hourly 0.9 https://trial.medpath.com/news/avicanna-launches-phase-i-clinical-trial-to-determine-optimal-thc-dosing-for-anxiety-treatment 2026-03-16T21:09:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/avicanna-launches-phase-i-clinical-trial-to-determine-optimal-thc-dosing-for-anxiety-treatment 2026-03-16T21:09:22+00:00 hourly 0.9 https://trial.medpath.com/news/sona-nanotech-s-targeted-hyperthermia-therapy-shows-38-tumor-clearance-in-colorectal-cancer-study 2026-03-16T21:08:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sona-nanotech-s-targeted-hyperthermia-therapy-shows-38-tumor-clearance-in-colorectal-cancer-study 2026-03-16T21:08:59+00:00 hourly 0.9 https://trial.medpath.com/news/sartorius-unveils-eveo-platform-to-transform-cell-therapy-manufacturing-with-90-cost-reduction 2026-03-16T21:07:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sartorius-unveils-eveo-platform-to-transform-cell-therapy-manufacturing-with-90-cost-reduction 2026-03-16T21:07:33+00:00 hourly 0.9 https://trial.medpath.com/news/neximmune-advances-nex-ile12-immunotherapy-in-phase-1-trials-with-promising-safety-profile 2026-03-16T21:07:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/neximmune-advances-nex-ile12-immunotherapy-in-phase-1-trials-with-promising-safety-profile 2026-03-16T21:07:31+00:00 hourly 0.9 https://trial.medpath.com/news/fda-issues-first-formal-guidance-on-form-483-response-requirements-for-drug-manufacturers 2026-03-16T21:07:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-issues-first-formal-guidance-on-form-483-response-requirements-for-drug-manufacturers 2026-03-16T21:07:20+00:00 hourly 0.9 https://trial.medpath.com/news/egret-therapeutics-moves-to-acquire-full-ownership-of-first-in-class-pd-1-agonist-for-stroke-related-brain-swelling 2026-03-16T21:06:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/egret-therapeutics-moves-to-acquire-full-ownership-of-first-in-class-pd-1-agonist-for-stroke-related-brain-swelling 2026-03-16T21:06:23+00:00 hourly 0.9 https://trial.medpath.com/news/prodeon-medical-s-urocross-expander-system-receives-fda-clearance-for-non-permanent-bph-treatment 2026-03-16T21:05:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/prodeon-medical-s-urocross-expander-system-receives-fda-clearance-for-non-permanent-bph-treatment 2026-03-16T21:05:35+00:00 hourly 0.9 https://trial.medpath.com/news/black-diamond-therapeutics-reports-promising-phase-2-data-for-silevertinib-in-egfr-mutant-cancers 2026-03-16T20:29:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/black-diamond-therapeutics-reports-promising-phase-2-data-for-silevertinib-in-egfr-mutant-cancers 2026-03-16T20:29:00+00:00 hourly 0.9 https://trial.medpath.com/news/blue-light-cystoscopy-shows-superior-detection-and-cost-effectiveness-in-high-risk-bladder-cancer-management 2026-03-16T17:09:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/blue-light-cystoscopy-shows-superior-detection-and-cost-effectiveness-in-high-risk-bladder-cancer-management 2026-03-16T17:09:00+00:00 hourly 0.9 https://trial.medpath.com/news/amlogenyx-reports-promising-preclinical-data-for-am805-gene-therapy-in-alzheimer-s-disease-treatment 2026-03-16T17:06:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/amlogenyx-reports-promising-preclinical-data-for-am805-gene-therapy-in-alzheimer-s-disease-treatment 2026-03-16T17:06:58+00:00 hourly 0.9 https://trial.medpath.com/news/avethera-gmbh-acquires-fraunhofer-item-braunschweig-site-to-expand-biopharmaceutical-manufacturing 2026-03-16T17:05:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/avethera-gmbh-acquires-fraunhofer-item-braunschweig-site-to-expand-biopharmaceutical-manufacturing 2026-03-16T17:05:43+00:00 hourly 0.9 https://trial.medpath.com/news/ternary-therapeutics-secures-ps3-6m-to-advance-ai-driven-molecular-glue-drug-discovery-platform 2026-03-16T17:05:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ternary-therapeutics-secures-ps3-6m-to-advance-ai-driven-molecular-glue-drug-discovery-platform 2026-03-16T17:05:16+00:00 hourly 0.9 https://trial.medpath.com/news/illumina-partners-with-veritas-genetics-to-integrate-whole-genome-sequencing-into-health-insurance-plans 2026-03-16T17:05:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/illumina-partners-with-veritas-genetics-to-integrate-whole-genome-sequencing-into-health-insurance-plans 2026-03-16T17:05:12+00:00 hourly 0.9 https://trial.medpath.com/news/sentynl-therapeutics-licenses-progerinin-for-hutchinson-gilford-progeria-syndrome-treatment 2026-03-16T17:05:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sentynl-therapeutics-licenses-progerinin-for-hutchinson-gilford-progeria-syndrome-treatment 2026-03-16T17:05:06+00:00 hourly 0.9 https://trial.medpath.com/news/elevara-medicines-initiates-phase-2b-trial-of-novel-cdk4-6-inhibitor-elv001-for-treatment-resistant-rheumatoid-arthritis 2026-03-16T17:04:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/elevara-medicines-initiates-phase-2b-trial-of-novel-cdk4-6-inhibitor-elv001-for-treatment-resistant-rheumatoid-arthritis 2026-03-16T17:04:30+00:00 hourly 0.9 https://trial.medpath.com/news/lundbeck-reports-positive-phase-1b-results-for-lu-af28996-in-advanced-parkinson-s-disease 2026-03-16T13:07:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lundbeck-reports-positive-phase-1b-results-for-lu-af28996-in-advanced-parkinson-s-disease 2026-03-16T13:07:48+00:00 hourly 0.9 https://trial.medpath.com/news/blood-test-shows-96-accuracy-in-detecting-glioblastoma-offering-hope-for-earlier-diagnosis 2026-03-16T13:05:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/blood-test-shows-96-accuracy-in-detecting-glioblastoma-offering-hope-for-earlier-diagnosis 2026-03-16T13:05:27+00:00 hourly 0.9 https://trial.medpath.com/news/scinus-group-secures-eur3-million-to-advance-cell-therapy-manufacturing-platform 2026-03-16T13:05:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/scinus-group-secures-eur3-million-to-advance-cell-therapy-manufacturing-platform 2026-03-16T13:05:03+00:00 hourly 0.9 https://trial.medpath.com/news/grit-biotechnologies-receives-fda-ind-clearance-for-gene-edited-til-therapy-gt307 2026-03-16T13:04:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/grit-biotechnologies-receives-fda-ind-clearance-for-gene-edited-til-therapy-gt307 2026-03-16T13:04:55+00:00 hourly 0.9 https://trial.medpath.com/news/organoid-science-receives-world-s-first-ind-approval-for-intestinal-organoid-therapy-in-crohn-s-disease 2026-03-16T13:04:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/organoid-science-receives-world-s-first-ind-approval-for-intestinal-organoid-therapy-in-crohn-s-disease 2026-03-16T13:04:51+00:00 hourly 0.9 https://trial.medpath.com/news/super-vision-technology-s-i-nys-implant-receives-china-approval-as-world-s-first-treatment-for-congenital-nystagmus 2026-03-16T13:04:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/super-vision-technology-s-i-nys-implant-receives-china-approval-as-world-s-first-treatment-for-congenital-nystagmus 2026-03-16T13:04:37+00:00 hourly 0.9 https://trial.medpath.com/news/piramal-pharma-solutions-achieves-major-adc-manufacturing-milestone-with-1500th-batch-delivery 2026-03-16T13:04:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/piramal-pharma-solutions-achieves-major-adc-manufacturing-milestone-with-1500th-batch-delivery 2026-03-16T13:04:06+00:00 hourly 0.9 https://trial.medpath.com/news/novel-protein-carrier-boosts-paclitaxel-solubility-3600-fold-in-targeted-cancer-therapy 2026-03-16T09:06:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-protein-carrier-boosts-paclitaxel-solubility-3600-fold-in-targeted-cancer-therapy 2026-03-16T09:06:24+00:00 hourly 0.9 https://trial.medpath.com/news/gen-pharmaceuticals-receives-ethical-approval-for-phase-ii-parkinson-s-disease-trial-of-mitochondrial-targeting-drug-sul-238 2026-03-16T09:05:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gen-pharmaceuticals-receives-ethical-approval-for-phase-ii-parkinson-s-disease-trial-of-mitochondrial-targeting-drug-sul-238 2026-03-16T09:05:52+00:00 hourly 0.9 https://trial.medpath.com/news/bayer-s-finerenone-achieves-primary-endpoint-in-phase-iii-find-ckd-trial-for-non-diabetic-chronic-kidney-disease 2026-03-16T09:04:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bayer-s-finerenone-achieves-primary-endpoint-in-phase-iii-find-ckd-trial-for-non-diabetic-chronic-kidney-disease 2026-03-16T09:04:36+00:00 hourly 0.9 https://trial.medpath.com/news/life-sciences-industry-leaders-call-for-systemic-change-to-address-persistent-gender-gap-in-stem 2026-03-16T06:26:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/life-sciences-industry-leaders-call-for-systemic-change-to-address-persistent-gender-gap-in-stem 2026-03-16T06:26:14+00:00 hourly 0.9 https://trial.medpath.com/news/cutia-therapeutics-receives-nmpa-approval-for-topical-dutasteride-clinical-trial-in-androgenetic-alopecia 2026-03-16T05:03:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cutia-therapeutics-receives-nmpa-approval-for-topical-dutasteride-clinical-trial-in-androgenetic-alopecia 2026-03-16T05:03:46+00:00 hourly 0.9 https://trial.medpath.com/news/tetratherix-launches-precision-medicine-platform-with-30m-partnership-for-nasal-drug-delivery 2026-03-16T05:03:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tetratherix-launches-precision-medicine-platform-with-30m-partnership-for-nasal-drug-delivery 2026-03-16T05:03:38+00:00 hourly 0.9 https://trial.medpath.com/news/blinklab-advances-autism-diagnostic-device-toward-fda-clearance-with-pivotal-trial-launch 2026-03-16T05:03:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/blinklab-advances-autism-diagnostic-device-toward-fda-clearance-with-pivotal-trial-launch 2026-03-16T05:03:36+00:00 hourly 0.9 https://trial.medpath.com/news/percheron-therapeutics-raises-2-2-million-to-advance-vista-targeting-cancer-therapy-hmbd-002 2026-03-16T01:03:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/percheron-therapeutics-raises-2-2-million-to-advance-vista-targeting-cancer-therapy-hmbd-002 2026-03-16T01:03:17+00:00 hourly 0.9 https://trial.medpath.com/news/racura-oncology-receives-approval-for-phase-1-trial-of-rc220-combination-therapy-in-egfr-mutant-lung-cancer 2026-03-16T01:03:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/racura-oncology-receives-approval-for-phase-1-trial-of-rc220-combination-therapy-in-egfr-mutant-lung-cancer 2026-03-16T01:03:06+00:00 hourly 0.9 https://trial.medpath.com/news/ai-designed-mrna-cancer-vaccine-shows-promise-in-canine-trial-sparks-human-treatment-potential 2026-03-15T13:04:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ai-designed-mrna-cancer-vaccine-shows-promise-in-canine-trial-sparks-human-treatment-potential 2026-03-15T13:04:42+00:00 hourly 0.9 https://trial.medpath.com/news/firefly-neuroscience-discovers-brain-wave-biomarkers-to-distinguish-adhd-subtypes 2026-03-14T21:05:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/firefly-neuroscience-discovers-brain-wave-biomarkers-to-distinguish-adhd-subtypes 2026-03-14T21:05:54+00:00 hourly 0.9 https://trial.medpath.com/news/ono-pharmaceutical-completes-two-key-oncology-studies-as-pipeline-advances 2026-03-14T21:05:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ono-pharmaceutical-completes-two-key-oncology-studies-as-pipeline-advances 2026-03-14T21:05:21+00:00 hourly 0.9 https://trial.medpath.com/news/fibrogen-refocuses-on-oncology-pipeline-following-china-divestiture-extends-runway-through-2028 2026-03-14T21:05:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fibrogen-refocuses-on-oncology-pipeline-following-china-divestiture-extends-runway-through-2028 2026-03-14T21:05:19+00:00 hourly 0.9 https://trial.medpath.com/news/scientists-engineer-bacteria-to-boost-doxorubicin-production-by-180-overcoming-50-year-manufacturing-challenge 2026-03-14T21:04:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/scientists-engineer-bacteria-to-boost-doxorubicin-production-by-180-overcoming-50-year-manufacturing-challenge 2026-03-14T21:04:33+00:00 hourly 0.9 https://trial.medpath.com/news/uk-patient-becomes-first-to-receive-experimental-antibody-drug-conjugate-for-metastatic-prostate-cancer 2026-03-14T17:03:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/uk-patient-becomes-first-to-receive-experimental-antibody-drug-conjugate-for-metastatic-prostate-cancer 2026-03-14T17:03:45+00:00 hourly 0.9 https://trial.medpath.com/news/duke-clinical-trial-shows-promising-results-for-first-line-immunotherapy-in-metastatic-colorectal-cancer 2026-03-14T17:03:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/duke-clinical-trial-shows-promising-results-for-first-line-immunotherapy-in-metastatic-colorectal-cancer 2026-03-14T17:03:21+00:00 hourly 0.9 https://trial.medpath.com/news/korean-biotech-companies-to-showcase-next-generation-cancer-therapies-at-aacr-2026 2026-03-14T13:03:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/korean-biotech-companies-to-showcase-next-generation-cancer-therapies-at-aacr-2026 2026-03-14T13:03:03+00:00 hourly 0.9 https://trial.medpath.com/news/google-s-amie-ai-assistant-demonstrates-doctor-level-diagnostic-performance-in-first-real-world-clinical-trial 2026-03-14T09:04:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/google-s-amie-ai-assistant-demonstrates-doctor-level-diagnostic-performance-in-first-real-world-clinical-trial 2026-03-14T09:04:56+00:00 hourly 0.9 https://trial.medpath.com/news/vimgreen-s-a2a-receptor-antagonist-vg081821-receives-first-global-ind-approval-for-nash-treatment 2026-03-14T09:04:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vimgreen-s-a2a-receptor-antagonist-vg081821-receives-first-global-ind-approval-for-nash-treatment 2026-03-14T09:04:09+00:00 hourly 0.9